Professor Robert Storey

BSc, BM, DM, FRCP, FESC

Clinical Medicine, School of Medicine and Population Health

Professor of Clinical Cardiology

r.f.storey@sheffield.ac.uk
+44 114 305 2055

Northern General Hospital

Full contact details

Professor Robert Storey
Clinical Medicine, School of Medicine and Population Health
Northern General Hospital
Herries Road
Sheffield
S5 7AU

Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

I joined the University of Sheffield in 2002 as a Senior Clinical Lecturer in Cardiology and subsequently became Professor of Cardiology in January 2011. I am Clinical Lead for the Cardiovascular Disease research theme and Director of the Cardiovascular Research Unit. I am also Academic Director for the Cardiology and Cardiothoracic Surgery Directorate and an Honorary Consultant Cardiologist with Sheffield Teaching Hospitals National Health Service Foundation Trust.

I have a special interest in atherothrombosis and antithrombotic therapy in the management of ischaemic heart disease, including coronary intervention. I was Chair of the European Society of Cardiology (ESC) Working Group on Thrombosis 2012-2014 and have been a member of 4 Task Forces for ESC Guidelines as well as author of many ESC position papers. I received a BSc Hons in biochemistry from the University of York, UK, in 1985 before going on to obtain my medical degree (BM) from the University of Southampton in 1989. After completing general professional training, I trained in the fields of Cardiology and General (Internal) Medicine at Queen´s Medical Centre in Nottingham, completing specialist training in both fields in 2001.

During that time, I developed a keen interest in thrombosis research, studying platelet biology and pharmacology, conducting clinical research studies in patients with cardiovascular disease and obtaining a postgraduate degree in research (DM) from the University of Nottingham.

I have been an Executive/Steering Committee member of numerous international clinical trials such as the PLATO, PEGASUS-TIMI 54, AUGUSTUS and COMPLETE studies and am currently a member of the steering committees for the RAPID-CTCA, SENIOR-RITA, CLEAR-SYNERGY and other studies.

Research interests

My principal research area is atherothrombosis. My particular interests are:

platelet pharmacology
relationships between inflammation and atherothrombosis
fibrin clot properties and thrombotic risk
cardiovascular clinical trials
clinical practice guidelines

Current projects

Numerous projects in the areas of antithrombotic therapy and acute coronary syndromes.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Orme RC, Parker WAE, Thomas MR, Judge HM, Baster K, Sumaya W, Morgan KP, McMellon HC, Richardson JD, Grech ED , Wheeldon NM et al (2018) Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, Himmelmann A, Ajjan RA & Storey RF (2018) Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: A PLATO substudy. European Heart Journal, 39(13), 1078-1085. View this article in WRRO
Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF , Steg PG et al (2016) Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology, 67(10), 1145-1154. View this article in WRRO
Thomas MR, Outteridge SN, Ajjan RA, Phoenix F, Sangha GK, Faulkner RE, Ecob R, Judge HM, Khan H, West LE , Dockrell DH et al (2015) Platelet P2Y 12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 35(12), 2562-2570. View this article in WRRO
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K , Bengtsson O et al (2015) Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 372(19), 1791-1800.
Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier Á, Chettibi M, Goodman SG , Hammett CJ et al (2014) Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 371(11), 1016-1027.
West LE, Steiner T, Judge HM, Francis SE & Storey RF (2014) Vessel wall, not platelet, P2Y12 potentiates early atherogenesis.. Cardiovasc Res, 102(3), 429-435.
Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A , Cairns R et al (2011) Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.. Eur Heart J, 32(23), 2945-2953.
Patil SB, Jackman LE, Francis SE, Judge HM, Nylander S & Storey RF (2010) Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.. Arterioscler Thromb Vasc Biol, 30(12), 2385-2391.
Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC & Wallentin L (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.. J Am Coll Cardiol, 56(18), 1456-1462.
Storey RF, Bliden KP, Patil SB, Karunakaran A, Ecob R, Butler K, Teng R, Wei C, Tantry US, Gurbel PA & ONSET/OFFSET Investigators (2010) Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.. J Am Coll Cardiol, 56(3), 185-193.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H , Mahaffey KW et al (2009) Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. NEW ENGL J MED, 361(11), 1045-1057.
Evans DJW, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K, Norman KE, Francis SE & Storey RF (2009) Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis.. Circulation, 119(1), 116-122.

All publications

Journal articles

Sammut M, Lim CJ, Cheong SC, Singh M, Lee J, Storey RF, Braidley P, Briffa N, Cartwright N, Chetty G , Forlani S et al (2024) Long-term efficacy of concomitant surgical ablation for atrial fibrillation with cardiac surgery. European Heart Journal, 45(Supplement_1).
Morris PD, Williams GJ, Taylor DJ, Al Baraikan A, Haley H, Ghobrial M, Gosling R, Newman TA, Wood DA, Cairns JA , Ramasundarahettige C et al (2024) Virtual physiological analysis of non-culprit disease in patients with STEMI and multivessel disease: a substudy of the COMPLETE trial. European Heart Journal, 45(Supplement_1).
Storey RF, Deanfield J, James S, Ajjan R, Eriksson N, Erlinge D, De Belder M, Gale CP, Zaman A, Hofmann R , Jiang Y et al (2024) Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline glycaemic status and body mass index: a DAPA-MI substudy. European Heart Journal, 45(Supplement_1).
Parker WAE, Elamin N, Sammut MA, Rahman MEF, Konstantinidis KV, Mcmellon HC, Moyle BJE, Patel M, El Khoury J, Surujbally R & Storey RF (2024) Detection of chronic obstructive pulmonary disease and frequency of cardiopulmonary events in patients with a significant smoking history hospitalised for acute myocardial infarction. European Heart Journal, 45(Supplement_1).
Erlinge D, James S, Deanfield J, Eriksson N, De Belder M, Jones DA, Sederholm Lawesson S, Austin D, Szummer K, Ridderstrale W , Langkilde AM et al (2024) Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy. European Heart Journal, 45(Supplement_1).
Sammut MA & Storey RF (2024) Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 22(9), 471-482.
Valgimigli M, Landi A, Angiolillo DJ, Baber U, Bhatt DL, Bonaca MP, Capodanno D, Cohen DJ, Gibson CM, James S , Kimura T et al (2024) Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation, 150(4), 317-335.
d'Entremont M-A, Lee SF, Mian R, Kedev S, Montalescot G, Cornel JH, Stankovic G, Moreno R, Storey RF, Henry TD , Skuriat E et al (2024) Design and Rationale of the CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction. American Heart Journal.
Guimarães PO, Lopes RD, Wojdyla DM, Alexander JH, Goodman SG, Aronson R, Halvorsen S, Sinnaeve P, Vinereanu D, Storey RF , Berwanger O et al (2024) Antithrombotic Strategies According to Age: Insights From the AUGUSTUS Trial. The American Journal of Medicine.
(2024) Factor XI and XIa inhibition: a new approach to anticoagulant therapy. British Journal of Cardiology.
van den Broek WWA, Gimbel ME, Hermanides RS, Runnett C, Storey RF, Knaapen P, Emans ME, Oemrawsingh RM, Cooke J, Galasko G , Walhout R et al (2024) The impact of patient-reported frailty on cardiovascular outcomes in elderly patients after non-ST-acute coronary syndrome. International Journal of Cardiology, 131940-131940.
Jolly SS, Lee SF, Mian R, Kedev S, Lavi S, Moreno R, Montalescot G, Hillani A, Henry TD, Asani V , Storey RF et al (2024) SYNERGY—Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry. The American Journal of Cardiology.
Storey RF (2024) Antiplatelet Therapy After PCI: The Art and Science of De-Escalation. Circulation, 149(8), 601-604.
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan G-A, Dweck MR, Galbraith M , Gilard M et al (2024) [2023 ESC Guidelines for the management of acute coronary syndromes].. G Ital Cardiol (Rome), 25(2 Suppl 2), e1-e112.
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan G-A, Dweck MR, Galbraith M , Gilard M et al (2024) 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care, 13(1), 55-161.
(2023) Drug therapies for stroke prevention. British Journal of Cardiology.
Van Den Broek WWA, Hermanides RS, Runnet R, Storey RF, Knaapen P, Emans ME, Oemrawsingh RM, Walhout R, Von Birgelen C, Liem A , Van 'T Hof AWJ et al (2023) Impact of patient-reported frailty on cardiovascular outcomes in elderly patients with non-ST-elevation myocardial infarction. European Heart Journal, 44(Supplement_2).
Al Said S, Kaier K, Sumaya W, Alsaid D, Duerschmied D, Storey RF, Gibson CM, Westermann D & Alabed S (2023) Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. European Heart Journal, 44(Supplement_2).
Parker WAE, Judge HM, Nelson TA, Elamin N, Williamson G, Shaji N, Middle J, Hanson JA, Bridge CM, Mcmellon HC , Ajjan RA et al (2023) Interactions between aspirin and ticagrelor during experimental human endotoxaemia. European Heart Journal, 44(Supplement_2).
Patel SM, Bonaca MP, Morrow DA, Palazzolo MG, Jarolim P, Steg PG, Bhatt DL, Storey RF, Sabatine MS & O'Donoghue ML (2023) Lipoprotein(a) and Benefit of Antiplatelet Therapy. JACC: Advances, 2(9), 100675-100675.
Tiong D, Pinilla N, Wood D, Mehran R, Storey R, Feldman L, Moreno R, Rao S, Cantor W, Welsh R , Cohen E et al (2023) TCT-623 Effects of Complete Revascularization in Relation to Left Ventricular Function in Patients With STEMI and Multivessel Disease: Data from the COMPLETE Randomized trial. Journal of the American College of Cardiology, 82(17), B250-B251.
Oqab Z, Kunadian V, Wood DA, Storey RF, Rao SV, Mehran R, Pinilla-Echeverri N, Mani T, Boone RH, Kassam S , Bossard M et al (2023) Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial. Circulation: Cardiovascular Interventions, 16(9).
Wang K-L, Meah MN, Bularga A, Oatey K, O'Brien R, Smith JE, Curzen N, Kardos A, Keating L, Felmeden D , Storey RF et al (2023) Early computed tomography coronary angiography and preventative treatment in patients with suspected acute coronary syndrome: A secondary analysis of the RAPID-CTCA trial. American Heart Journal, 266, 138-148.
James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Björkgren I, Johansson PA, Langkilde AM, Ridderstråle W, Parvaresh Rizi E , Deanfield J et al (2023) Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction. American Heart Journal.
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan G-A, Dweck MR, Galbraith M , Gilard M et al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal, 44(38), 3720-3826.
Kaski JC, Lluch N, Lopez-Sendon J-L, Gorog DA, Antorrena-Miranda I, Avanzas P, Herrero Puente P, Sionis A, González-Juanatey JR, Íñiguez A , Cordero A et al (2023) Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial. International Journal of Cardiology, 131291-131291.
Moss A, Daghem M, Tzolos E, Meah MN, Wang K-L, Bularga A, Adamson PD, Kwiecinski J, Fletcher A, Dawson D , Arumugam P et al (2023) Coronary Atherosclerotic Plaque Activity and Future Coronary Events. JAMA Cardiology, 8(8), 755-755.
Capodanno D, Mehran R, Krucoff MW, Baber U, Bhatt DL, Capranzano P, Collet J-P, Cuisset T, De Luca G, De Luca L , Farb A et al (2023) Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium.. Circulation, 147(25), 1933-1944.
Storey RF & Parker WAE (2023) Thrombotic Coronary Occlusion and Reperfusion: Unraveling the Determinants. Journal of the American College of Cardiology, 81(19), 1933-1936.
Valgimigli M, Aboyans V, Angiolillo D, Atar D, Capodanno D, Halvorsen S, James S, Jüni P, Kunadian V, Landi A , Leonardi S et al (2023) Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. European Heart Journal - Cardiovascular Pharmacotherapy, 9(5), 462-496.
Davidsson P, Eketjäll S, Eriksson N, Walentinsson A, Becker RC, Cavallin A, Bogstedt A, Collén A, Held C, James S , Siegbahn A et al (2023) Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease. Cardiovascular Research, 119(7), 1596-1605.
Parker WAE, Angiolillo DJ, Rollini F, Franchi F, Bonaca MP, Bhatt DL, Steg PG, Orme RC, Thomas MR, Judge HM , Sabatine MS et al (2023) Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Vascular Pharmacology, 149, 107145-107145.
Hassan K, Geidel S, Zamvar V, Tanaka K, Knezevic-Woods Z, Wendt D, Deliargyris EN, Storey RF & Schmoeckel M (2023) Intraoperative ticagrelor removal via hemoadsorption during on-pump coronary artery bypass grafting. JTCVS Open.
Varian FL, Parker WAE, Fotheringham J & Storey RF (2023) Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum. Platelets, 34(1).
Iqbal A, Storey RF & Ajjan RA (2022) Prolonged Inflammatory Response Post-Hypoglycemia: Mechanistic Insights Into the Relationship Between Low Glucose and Cardiovascular Risk. Diabetes, 71(12), 2483-2485.
Batra G, Lindbäck J, Becker RC, Harrington RA, Held C, James SK, Kempf T, Lopes RD, Mahaffey KW, Steg PG , Storey RF et al (2022) Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.. J Am Coll Cardiol, 80(18), 1735-1747.
Elamin N, Ow KW, Parker WAE, Nelson TA, Middle J, Hanson J, Moyle B, Krishnamurthy A, Barmby D, Morgan K , Adam Z et al (2022) Oral Presentation No. 84 Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention. Cardiovascular Research, 118(Supplement_2).
Patel S, Morrow D, Bonaca M, Palazzolo M, Jarolim P, Steg PG, Bhatt D, Storey R, Cohen M, Braunwald E , Sabatine M et al (2022) Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial. European Heart Journal, 43(Supplement_2).
Oqab Z, Kunadian V, Wood D, Rao S, Mehran R, Pinilla N, Storey R, Boone R, Sibbald M, Valettas N , Moreno R et al (2022) TCT-36 Complete Revascularization Versus Culprit Lesion–Only PCI in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: A Subgroup Analysis of the COMPLETE Trial. Journal of the American College of Cardiology, 80(12), B15-B15.
Bainey K, Cairns J, Rao S, Wood D, Storey R, Mehran R, Cantor W, Lavi S, Rodes-Cabau J, Dzavik V , Dehghani P et al (2022) TCT-35 Effects of Complete Revascularization According to Age in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel: Insights From the COMPLETE Trial. Journal of the American College of Cardiology, 80(12), B15-B15.
Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I, Geisler T, Hinterbuchner L , Ibanez B et al (2022) 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. European Heart Journal, 43(39), 3826-3924.
Matejic-Spasic M, Hassan K, Thielmann M, Geidel S, Storey RF, Schmoeckel M, Adamson H, Deliargyris EN & Wendt D (2022) Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review. Journal of Thoracic Disease, 14(8), 3030-3044.
Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O'Brien R, Storey RF, Curzen N, Keating L, Kardos A , Felmeden D et al (2022) Early computed tomography coronary angiography in adults presenting with suspected acute coronary syndrome: the RAPID-CTCA RCT.. Health Technol Assess, 26(37), 1-114.
Capodanno D, Baber U, Bhatt DL, Collet J-P, Dangas G, Franchi F, Gibson CM, Gwon H-C, Kastrati A, Kimura T , Lemos PA et al (2022) P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.. Nat Rev Cardiol.
Tripathi R, Morales J, Lee V, Gibson CM, Mack MJ, Schneider DJ, Douketis J, Sellke FW, Ohman EM, Thourani VH , Storey RF et al (2022) Antithrombotic Drug Removal from Whole Blood Using Haemoadsorption with a Porous Polymer Bead Sorbent.. Eur Heart J Cardiovasc Pharmacother.
Wang K-L, Roobottom C, Smith JE, Goodacre S, Oatey K, O'Brien R, Storey RF, Curzen N, Keating L, Kardos A , Felmeden D et al (2022) Presentation cardiac troponin and early computed tomography coronary angiography in patients with suspected acute coronary syndrome: a pre-specified secondary analysis of the RAPID-CTCA trial. European Heart Journal: Acute Cardiovascular Care. View this article in WRRO
Meah MN, Tzolos E, Wang K-L, Bularga A, Dweck MR, Curzen N, Kardos A, Keating L, Storey RF, Mills NL , Slomka PJ et al (2022) Plaque Burden and 1-Year Outcomes in Acute Chest Pain. JACC: Cardiovascular Imaging.
Ono M, Onuma Y, Kawashima H, Hara H, Gao C, Wang R, O'Leary N, Benit E, Janssens L, Ferrario M , Żurakowski A et al (2022) Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention : insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions.
Meah M, Tzolos E, Wang K-L, Bularga A, Dweck M, Curzen N, Kardos A, Keating L, Storey RF, Mills NL , Dey D et al (2022) THE PROGNOSTIC VALUE OF PLAQUE IN PATIENTS WITH ACUTE CHEST PAIN. Journal of the American College of Cardiology, 79(9), 1220.
Bonaca MP, Lesén E, Giannitsis E, Jernberg T, Maggioni AP, Ariza-Solé A, Berg JMT, Bhalla N & Storey RF (2022) CLINICAL CORRELATES OF ISCHEMIC AND BLEEDING RISK IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION TREATED WITH EXTENDED DUAL ANTIPLATELET THERAPY WITH TICAGRELOR 60 MG: INSIGHTS FROM ALETHEIA, A MULTI-COUNTRY OBSERVATIONAL STUDY. Journal of the American College of Cardiology, 79(9), 1140.
Jolly SS, Mian R, Kedev S, Lavi S, Moreno R, Montalescot G, Henry TD, Asani V, Storey RF, Silvain J , Spratt JCS et al (2022) SYNERGY- EVEROLIMUS ELUTING STENT WITH A BIOABSORBABLE POLYMER IN ST ELEVATION MYOCARDIAL INFARCTION- CLEAR SYNERGY OASIS-9 TRIAL. Journal of the American College of Cardiology, 79(9), 575.
Elamin N, Nelson T, Parker W, Varian F, Williamson G, McMellon H, Hanson J, Middle J, Bridge C, Judge HM , Briffa N et al (2022) THROMBOINFLAMMATORY RESPONSE TO ON-PUMP CORONARY ARTERY BYPASS GRAFT SURGERY LEADS TO IMPAIRED PLATELET REACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology, 79(9), 1094-1094.
Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, Duerschmied D, Smyth SS, Parker WAE, Ajjan RA , Vilahur G et al (2022) Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.. Nat Rev Cardiol.
Parker WAE, Sagar R, Kurdee Z, Hawkins F, Naseem KM, Grant PJ, Storey RF & Ajjan RA (2021) A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. Cardiovascular Diabetology, 20(1).
Batra G, Lindback J, Becker RC, Harrington RA, Held C, James SK, Kempf T, Lagerqvist B, Lopes RD, Tricoci P , Mahaffey KW et al (2021) Abstract 13221: The Biomarker-Based ABC-ACS (Age, Biomarkers, Clinical History) Score Can Predict Major Bleeding Better Than Other Contemporary Scores in Patients on Dual Antiplatelet Therapy After Coronary Revascularization: Results of a Large Derivation and Validation Study. Circulation, 144(Suppl_1), a13221-a13221.
Guimaraes P, Lopes RD, Wojdyla D, Alexander JH, Goodman SG, Aronson R, Halvorsen S, Sinnaeve PR, Vinereanu D, Storey RF , Berwanger OB et al (2021) Abstract 12512: Antithrombotic Strategies According to Age in Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the Augustus Trial. Circulation, 144(Suppl_1), a12512-a12512.
Ono M, Onuma Y, Kawashima H, Hara H, Gao C, Wang R, O’Leary N, Garg S, Juni P, Hamm C , Valgimigli M et al (2021) TCT-201 Impact of Proton Pump Inhibitors on Efficacy of Antiplatelet Strategies With Ticagrelor or Aspirin After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 78(19), B82-B83.
Hjort M, Eggers KM, Becker RC, Budaj A, Cornel JH, Giannitsis E, James SK, Katus HA, Ghukasyan Lakic T, Lindback J , Siegbahn A et al (2021) Temporal changes of biomarkers in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries. European Heart Journal, 42(Supplement_1).
Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O’Brien R, Storey RF, Curzen N, Keating L, Kardos A , Felmeden D et al (2021) Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. BMJ: British Medical Journal, 374. View this article in WRRO
Cubedo J, Padró T, Vilahur G, Crea F, Storey RF, Lopez Sendon JL, Kaski JC, Sionis A, Sans-Rosello J, Fernández-Peregrina E , Gallinat A et al (2021) Glycosylated apolipoprotein J in cardiac ischaemia: molecular processing and circulating levels in patients with acute ischaemic events.. Eur Heart J.
Parker WAE & Storey RF (2021) Ticagrelor monotherapy in CKD: better safety at what price?. Eur Heart J.
Valgimigli M, Storey RF, Sinnaeve PR, Riederer MA, Bernaud C & Frenoux J-M (2021) Selatogrel and other P2Y12 inhibitors’ putative off-target effects. Journal of Cardiovascular Pharmacology, Publish Ahead of Print.
Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T , Hamm C et al (2021) Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial. Journal of the American Heart Association, 10(17).
Crea F (2021) Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. European Heart Journal, 42(31), 2973-2985.
Sanderson NC, Parker WAE & Storey RF (2021) Ticagrelor : clinical development and future potential. Reviews in Cardiovascular Medicine, 22(2), 373-394.
Nelson TA, Parker WAE, Ghukasyan Lakic T, Westerbergh J, James SK, Siegbahn A, Becker RC, Himmelmann A, Wallentin L & Storey RF (2021) Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy.. Platelets, 1-7.
Gurbel PA, Tantry US & Storey RF (2021) International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests.. J Thromb Thrombolysis.
Al Said S, Alabed S, Sumaya W, Alsaid D, Kaier K, Duerschmied D, Storey RF, Gibson CM & Katus H (2021) Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. Cochrane Database of Systematic Reviews, 2021(5).
Dehghani P, Cantor W, Wang J, Wood D, Storey R, Mehran R, Bainey K, Welsh R, Rodes-Cabau J, Rao S , Lavi S et al (2021) COMPLETE REVASCULARIZATION IN PATIENTS UNDERGOING A PHARMACOINVASIVE STRATEGY FOR STEMI. Journal of the American College of Cardiology, 77(18), 933.
Collet JP, Thiele H, Barbato E, Bauersachs J, Dendale P, Edvardsen T, Gale CP, Jobs A, Lambrinou E, Mehilli J , Merkely B et al (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 42(14), 1289-1367.
Storey RF (2021) Ticagrelor versus prasugrel for PCI-managed myocardial infarction: the battle of the giants continues.. Heart.
Parker WAE & Storey RF (2021) Platelets and the Endothelium: Active Participants in Severe COVID-19 Infection. JACC: Basic to Translational Science, 6(3), 219-221.
Burnap SA, Mayr U, Shankar-Hari M, Cuello F, Thomas MR, Shah AM, Sabroe I, Storey RF & Mayr M (2021) A proteomics-based assessment of inflammation signatures in endotoxemia. Molecular & Cellular Proteomics, 20.
Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Oude Ophius T, Goudev A , Parkhomenko A et al (2021) Predictors, type, and impact of bleeding on the net clinical benefit of long‐term Ticagrelor in stable patients with prior myocardial infarction. Journal of the American Heart Association, 10(4).
Giannitsis E, Hamm CW, Boehm M, Cornel JH, Ferreiro JL, Frey N, Huber K, Kubica J, Navarese EP, Mehran R , Morais J et al (2021) Contra. EUROPEAN HEART JOURNAL, 42(31), 2979-2985.
Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T , Gale CP et al (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.. Rev Esp Cardiol (Engl Ed), 74(6), 544.
Thomas MR, James SK, Becker RC, Himmelmann A, Katus HA, Cannon CP, Steg PG, Siegbahn A, Lakic T, Storey RF & Wallentin L (2021) Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal. Acute Cardiovascular Care, 10(2), 153-163.
Parker WAE, Gorog DA, Geisler T, Vilahur G, Sibbing D, Rocca B & Storey RF (2020) Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. European Heart Journal Supplements, 22(Supplement_M), M26-M34.
Parker WAE, Schulte C, Barwari T, Phoenix F, Pearson SM, Mayr M, Grant PJ, Storey RF & Ajjan RA (2020) Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus : a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovascular Diabetology, 19(1). View this article in WRRO
Patel PN, Marston NA, Kamanu FK, Weng LC, Bonaca MP, Giugliano RP, Scirica BM, O'Donoghue ML, Cannon CP, ANDERSON CD , Bhatt DL et al (2020) Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 142(Suppl_3).
Storey R, Alexander JH, Wojdyla DM, Mehran R, Vora AN, Goodman SG, Aronson R, Windecker S, Granger CB & Lopes RD (2020) Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach. European Heart Journal, 41(Supplement_2).
Al-Mohammad A, Partridge DG, Fent G, Watson O, Lewis NT, Storey RF, Makris M & Chico TJ (2020) The Cardiac Complications of COVID-19; Many Publications, Multiple Uncertainties. Vascular Biology.
Collet J-P & Thiele H (2020) The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 41(37), 3495-3497.
Storey RF (2020) The long journey of individualizing antiplatelet therapy after acute coronary syndromes. European Heart Journal, 41(37), 3546-3548.
Sheth T, Pinilla-Echeverri N, Moreno R, Wang J, Wood DA, Storey RF, Mehran R, Bainey KR, Bossard M, Bangalore S , Schwalm J-D et al (2020) Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. Journal of the American College of Cardiology, 76(11), 1277-1286.
Zimarino M, Angiolillo DJ, Dangas G, Capodanno D, Barbato E, Hahn J-Y, Giustino G, Watanabe H, Costa F, Cuisset T , Rossini R et al (2020) Antithrombotic Therapy after Percutaneous Coronary Intervention of Bifurcation Lesions.. EuroIntervention.
Gregersen I, Michelsen AE, Lunde NN, Åkerblom A, Lakic TG, Skjelland M, Ryeng Skagen K, Becker RC, Lindbäck J, Himmelmann A , Solberg R et al (2020) Legumain in acute coronary syndromes: A substudy of the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American Heart Association, 9(17).
Gao C, Takahashi K, Garg S, Hara H, Wang R, Kawashima H, Ono M, Montalescot G, Haude M, Slagboom T , Vranckx P et al (2020) Regional variation in patients and outcomes in the GLOBAL LEADERS trial. International Journal of Cardiology.
Everett CC, Reynolds C, Fernandez C, Stocken DD, Sharples LD, Sathyapalan T, Heller S, Storey RF & Ajjan RA (2020) Rationale and design of the LIBERATES trial : protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction. Diabetes and Vascular Disease Research, 17(5).
Marquis-Gravel G, Dalgaard F, Jones AD, Lokhnygina Y, James SK, Harrington RA, Wallentin L, Steg PG, Lopes RD, Storey RF , Goodman SG et al (2020) Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology, 76(2), 162-171.
Ow KW, Parker W, Onwordi E & Storey RF (2020) 51 Adherence to cardiologist recommendations regarding extended duration of ticagrelor for patients undergoing PCI for myocardial infarction. Heart, 106(Suppl 2), a41-a41.
Pinilla-Echeverri N, Mehta SR, Wang J, Lavi S, Schampaert E, Cantor WJ, Bainey KR, Welsh RC, Kassam S, Mehran R , Storey RF et al (2020) Nonculprit Lesion Plaque Morphology in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 13(7).
(2020) Guía ESC 2019 sobre el diagnóstico y tratamiento de los síndromes coronarios crónicos. Revista Española de Cardiología, 73(6), 495.e1-495.e61.
Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, Bhatt DL, Steg PG, Storey RF, Johanson P , Wang Z et al (2020) Gut microbiota‐dependent trimethylamine N‐oxide and cardiovascular outcomes in patients with prior myocardial infarction: A nested case control study from the PEGASUS‐TIMI 54 trial. Journal of the American Heart Association, 9(10). View this article in WRRO
Furtado RHM, Venkateswaran RV, Nicolau JC, Gurmu Y, Bhatt DL, Storey RF, Steg PG, Magnani G, Goto S, Dellborg M , Kamensky G et al (2020) Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial. Journal of the American Heart Association, 9(10).
Braza-Boïls A, Barwari T, Gutmann C, Thomas MR, Judge HM, Joshi A, Pechlaner R, Shankar-Hari M, Ajjan RA, Sabroe I , Storey RF et al (2020) Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition. International Journal of Molecular Sciences, 21(8). View this article in WRRO
(2020) Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine, 382(16), 1568-1572.
d’Alessandro E, Becker C, Bergmeier W, Bode C, Bourne JH, Brown H, Buller HR, ten Cate-Hoek AJ, ten Cate V, van Cauteren YJM , Cheung YFH et al (2020) Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis, 120(04), 538-564.
Bainey KR, Engstroem T, Smits P, Gershlick A, James SK, Storey R, Wood DA, Mehran R, Cairns J & Mehta SR (2020) COMPLETE VERSUS CULPRIT-LESION-ONLY REVASCULARIZATION FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A COLLABORATIVE META-ANALYSIS OF RANDOMIZED TRIALS. Journal of the American College of Cardiology, 75(11), 15-15.
Marston N, Melloni G, Gurmu Y, Lee C, Kamanu F, Roselli C, Bonaca MP, Cavallari I, Giugliano R, Scirica BM , Bhatt D et al (2020) PERFORMANCE OF A NOVEL GENETIC RISK SCORE TO IDENTIFY RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CARDIOMETABOLIC DISEASE. Journal of the American College of Cardiology, 75(11), 2194-2194.
Hijazi Z, Alexander JH, Li Z, Wojdyla D, Mehran R, Granger CB, Bahit MC, Windecker S, Berwanger O, Halvorsen S , Sinnaeve P et al (2020) APIXABAN VERSUS WARFARIN AND ASPIRIN VERSUS PLACEBO ACCORDING TO RENAL FUNCTION AFTER ACUTE CORONARY SYNDROME OR PCI IN ATRIAL FIBRILLATION: INSIGHTS FROM THE AUGUSTUS TRIAL. Journal of the American College of Cardiology, 75(11), 298-298.
Parker WAE & Storey RF (2020) Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist. Expert Opinion on Emerging Drugs. View this article in WRRO
Ono M, Chichareon P, Tomaniak M, Kawashima H, Takahashi K, Kogame N, Modolo R, Hara H, Gao C, Wang R , Walsh S et al (2020) The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention : a prespecified sub-analysis of the GLOBAL LEADERS trial. Clinical Research in Cardiology. View this article in WRRO
Storey RF & Parker WAE (2020) Opiates and Clopidogrel Efficacy. Journal of the American College of Cardiology, 75(3), 301-303.
Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Himmelmann A, Ajjan RA & Storey RF (2020) Impaired fibrinolysis predicts adverse outcome in acute coronary syndrome patients with diabetes: A PLATO sub-study. Thrombosis and Haemostasis, 120(03), 412-422. View this article in WRRO
Capodanno D, Bhatt DL, Eikelboom JW, Fox KAA, Geisler T, Michael Gibson C, Gonzalez-Juanatey JR, James S, Lopes RD, Mehran R , Montalescot G et al (2020) Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 17(4), 242-257.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T , Agewall S et al (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 41(3), 407-477. View this article in WRRO
Tomaniak M, Chichareon P, Klimczak-Tomaniak D, Takahashi K, Kogame N, Modolo R, Wang R, Ono M, Hara H, Gao C , Kawashima H et al (2020) Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology, 109(7), 930-943.
Tomaniak M, Storey RF & Serruys PW (2020) Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit?. EuroIntervention, 15(13), 1125-1129.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T , Agewall S et al (2020) 2019 ghidul SEC pentru diagnosticul si managementul sindroamelor coronariene cronice: Grupul de lucru pentru diagnosticul si managementul sindroamelor coronariene cronice al societatii europeene de cardiologie (SEC). Revista Romana de Cardiologie, 30(3), 467-548.
Storey RF, Valgimigli M, Cuisset T, Capodanno D, Wijns W & Knuuti J (2020) Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines. European Heart Journal, 41(3), 483-484.
Tomaniak M, Chichareon P, Takahashi K, Kogame N, Modolo R, Chang CC, Spitzer E, Neumann F-J, Plante S, Hernández Antolin R , Jambrik Z et al (2020) Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 6(4), 222-230.
Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F , Corbalan R et al (2020) Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 41(17), 1625-1632.
Tavenier AH, Hermanides RS, Fabris E, Lapostolle F, Silvain J, ten Berg JM, Lassen JF, Bolognese L, Cantor WJ, Cequier Á , Chettibi M et al (2020) Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. Thrombosis and Haemostasis, 120(01), 065-074.
Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, Vinereanu D, Granger CB, Goodman SG, Aronson R , Windecker S et al (2020) Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation, 141(9), 781-783.
Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, Budaj A, Cornel JH, Himmelmann A, James SK , Siegbahn A et al (2020) ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis, 293, 35-41.
Wood DA, Cairns JA, Wang J, Mehran R, Storey RF, Nguyen H, Meeks B, Kunadian V, Tanguay J-F, Kim H-H , Cheema A et al (2019) Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 74(22), 2713-2723.
Storey RF, Gurbel PA, James S, Ten Berg JM, Tanguay J-F, Bernaud C, Frenoux J-M, Hmissi A, Van Der Harst P, Van't Hof AWJ , Dangas GD et al (2019) 2349: Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients. EUROPEAN HEART JOURNAL, 40(Suppl 1), 1355-1355. View this article in WRRO
Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, Meeks B, Di Pasquale G, López-Sendón J, Faxon DP , Mauri L et al (2019) Complete revascularization with multivessel PCI for myocardial infarction. New England Journal of Medicine, 381(15), 1411-1421. View this article in WRRO
Tomaniak M, Chichareon P, Modolo R, Plante S, Brunel P, Beygui F, Van Geuns R-J, Storey R, Hamm C, Steg PG , Vranckx P et al (2019) P6411Dyspnea in ticagrelor treated patients in the all-comer randomized GLOBAL LEADERS study and its association with clinical outcomes. European Heart Journal, 40(Supplement_1).
Tomaniak M, Chichareon P, Onuma Y, Deliargyris E, Takahashi K, Kogame N, Modolo R, Chang C-C, Rademaker-Havinga T, Storey R , Dangas G et al (2019) TCT-404 Benefit and Risks of Aspirin on Top of Ticagrelor in Acute Coronary Syndromes: Insights From the Randomized GLOBAL LEADERS Trial. Journal of the American College of Cardiology, 74(13), B400-B400.
Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C , Spinar J et al (2019) Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 5(4), 200-206. View this article in WRRO
Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, Modolo R, Chang CC, Rademaker-Havinga T, Storey RF , Dangas GD et al (2019) Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. JAMA Cardiology, 4(11), 1092-1092.
Andersen T, Ueland T, Ghukasyan Lakic T, Åkerblom A, Bertilsson M, Aukrust P, Michelsen AE, James SK, Becker RC, Storey RF , Wallentin L et al (2019) C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(11), 2402-2410.
Zwart B, Yazdani M, Ow KW, Richardson JD, Iqbal J, Gunn JP & Storey RF (2019) Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction. Platelets. View this article in WRRO
Schrör K, Kristensen SD, Storey RF & Verheugt FWA (2019) Aspirin and Primary Prevention in Patients with Diabetes—A Critical Evaluation of Available Randomized Trials and Meta-Analyses. Thrombosis and Haemostasis, 119(10), 1573-1582.
Geisler T, Jorbenadze R, Popov A-F, Mueller KL, Rath D, Droppa M, Schreieck J, Seizer P, Storey RF, Kristensen SD , Rubboli A et al (2019) Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice. Thrombosis and Haemostasis, 119(10), 1590-1605.
Verheugt FWA, ten Berg JM, Storey RF, Cuisset T & Granger CB (2019) Antithrombotics. Journal of the American College of Cardiology, 74(5), 699-711.
Mehta SR, Wood DA, Meeks B, Storey RF, Mehran R, Bainey KR, Nguyen H, Bangdiwala SI & Cairns JA (2019) Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. American Heart Journal, 215, 157-166.
Sibbing D, Aradi D, Alexopoulos D, ten Berg J, Bhatt DL, Bonello L, Collet J-P, Cuisset T, Franchi F, Gross L , Gurbel P et al (2019) Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 12(16), 1521-1537.
Sumaya W & Storey RF (2019) Does Risk of Premature Discontinuation of Dual-Antiplatelet Therapy Following PCI Attenuate With Increasing Age?. JACC: Cardiovascular Interventions, 12(10), 993-994.
Åkerblom A, Wojdyla DM, Wallentin L, James SK, de Souza Brito F, Steg PG, Cannon CP, Katus HA, Himmelmann A, Storey RF , Becker RC et al (2019) Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 213, 57-65.
Iqbal A, Prince LR, Novodvorsky P, Bernjak A, Thomas MR, Birch L, Lambert D, Kay LJ, Wright FJ, Macdonald IA , Jacques RM et al (2019) Effect of Hypoglycemia on Inflammatory Responses and the Response to Low Dose Endotoxemia in Humans.. Journal of Clinical Endocrinology and Metabolism, 104(4), 1187-1199. View this article in WRRO
Franchi F, James SK, Ghukasyan Lakic T, Budaj AJ, Cornel JH, Katus HA, Keltai M, Kontny F, Lewis BS, Storey RF , Himmelmann A et al (2019) Impact of diabetes Mellitus and Chronic Kidney Disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: Insights from the PLATO trial. Journal of the American Heart Association, 8(6). View this article in WRRO
Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J , Averkov O et al (2019) Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine. View this article in WRRO
Parker WAE & Storey RF (2019) Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal, 40(24), 1971-1974.
Sumaya W, Geisler T, Kristensen SD & Storey RF (2019) Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?. Thrombosis and Haemostasis. View this article in WRRO
Kessler T, Wolf B, Eriksson N, Kofink D, Mahmoodi BK, Rai H, Tragante V, Åkerblom A, Becker RC, Bernlochner I , Bopp R et al (2019) Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. Cardiovascular Research, 115(10), 1512-1518.
Parker WAE, Orme RC, Hanson J, Stokes HM, Bridge CM, Shaw PA, Sumaya W, Thorneycroft K, Petrucci G, Porro B , Judge HM et al (2019) Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 30(2), 148-157. View this article in WRRO
Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, Himmelmann A, James SK, Siegbahn A, Storey RF , Kontny F et al (2019) Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(2), 294-302.
Lapostolle F, van’t Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet J-P, Silvain J, Lassen JF, Heutz WMJM, Bolognese L , Cantor WJ et al (2019) Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. American Journal of Cardiovascular Drugs, 19(2), 173-183.
Fabris E, van't Hof A, Hamm CW, Lapostolle F, Lassen JF, Goodman SG, ten Berg JM, Bolognese L, Cequier A, Chettibi M , Hammett CJ et al (2019) Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. Catheterization and Cardiovascular Interventions, 93(7), E369-E377.
Lip GYH, Collet J-P, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M , Marin F et al (2019) 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). EP Europace, 21(2), 192-193.
Parker WAE, Eriksson N, Becker RC, Voora D, Åkerblom A, Himmelmann A, James SK, Wallentin L & Storey RF (2019) Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 30(5), 579-588.
Chow E, Iqbal A, Walkinshaw E, Phoenix F, Macdonald IA, Storey RF, Ajjan R & Heller SR (2018) Prolonged Prothrombotic Effects of Antecedent Hypoglycemia in Individuals With Type 2 Diabetes. Diabetes Care, 41(12), 2625-2633. View this article in WRRO
Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K , Magnani G et al (2018) Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54. Journal of the American Heart Association, 7(22). View this article in WRRO
Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A & Wallentin L (2018) Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. JAMA Cardiology, 3(12), 1160-1160.
Åstrand M, Amilon C, Röshammar D, Himmelmann A, Angiolillo DJ, Storey RF, Gurbel PA, Bonaca MP & Hamrén B (2018) Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.. British Journal of Clinical Pharmacology. View this article in WRRO
Bonaca MP, Giugliano RP, Nault P, Scirica BM, Pedersen TR, Bhatt DL, Keech AC, Storey RF, Steg PG, Cohen M , Goodrich EM et al (2018) Abstract 16771: Patient Selection for Therapies to Prevent Major Adverse Limb Events. Circulation, 138(Suppl_1).
Bonaca MP, Storey RF, Bhatt DL, Steg PG, Cohen M, Im KP, Johanson P, Braunwald EP & Sabatine MS (2018) Abstract 16658: Patient Selection for Long-Term Secondary Prevention With Ticagrelor: Insights From PEGASUS-TIMI 54. Circulation, 138(Suppl_1).
Orme RC, Parker WAE, Thomas MR, Judge HM, Baster K, Sumaya W, Morgan KP, McMellon HC, Richardson JD, Grech ED , Wheeldon NM et al (2018) Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
Lindholm D, James S, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A & Wallentin L (2018) P823Multiple biomarkers and cause-specific mortality in patients with acute coronary syndromes - Insights from the PLATO biomarker substudy. European Heart Journal, 39(suppl_1).
Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Himmelmann A, Ajjan RA & Storey RF (2018) P4404Impaired fibrin clot lysis persists at 1 month post ACS: a PLATO substudy. European Heart Journal, 39(suppl_1).
Capodanno D, Mehran R, Valgimigli M, Baber U, Windecker S, Vranckx P, Dangas G, Rollini F, Kimura T, Collet J-P , Gibson CM et al (2018) Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 15(8), 480-496.
Sumaya W, Parker W, Fretwell R, Hall I, Barmby D, Richardson J, Iqbal J, Adam Z, Morgan K, Gunn J , Mason A et al (2018) Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thrombosis and Haemostasis, 118(07), 1250-1256. View this article in WRRO
Angiolillo DJ, Price MJ & Storey RF (2018) Response by Angiolillo et al to Letter Regarding Article, “International Expert Consensus Document on Switching Platelet P2Y 12 Receptor Inhibiting Therapies”. Circulation, 137(21), 2310-2311.
Scirica BM, Bansilal S, Davoudi F, Armstrong PW, Clare RM, Schulte PJ, Pieper KS, Becker RC, James SK, Storey RF , Steg PG et al (2018) Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal, 202, 54-60.
Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, Himmelmann A, Ajjan RA & Storey RF (2018) Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: A PLATO substudy. European Heart Journal, 39(13), 1078-1085. View this article in WRRO
Borst O, Münzer P, Alnaggar N, Geue S, Tegtmeyer R, Rath D, Droppa M, Seizer P, Heitmeier S, Heemskerk JWM , Jennings LK et al (2018) Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction. Blood Advances, 2(6), 715-730.
Onwordi ENC, Parker WAE & Storey RF (2018) Dual antiplatelet therapy in the ‘real world’. Heart, 104(19), 1555-1556.
Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet J-P, Grove EL, Halvorsen S, Huber K, Morais J , Patrono C et al (2018) Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. European Heart Journal, 39(19), 1672-1686f.
Storey R (2018) Clot lysis time could identify heart attack patients most at risk of subsequent cardiovascular disease. BRITISH JOURNAL OF HOSPITAL MEDICINE, 79(3), 131-131.
Cavallari I, Morrow DA, Creager MA, Olin J, Bhatt DL, Steg PG, Storey RF, Cohen M, Scirica BS, Piazza G , Goodrich EL et al (2018) Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 137(7), 684-692.
Bansilal S, Bonaca MP, Cornel JH, Storey RF, Bhatt DL, Steg PG, Im K, Murphy SA, Angiolillo DJ, Kiss RG , Parkhomenko AN et al (2018) Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. Journal of the American College of Cardiology, 71(5), 489-496.
Storey R, Ardissino D, Vignali L, Cairns R, Becker R, Cannon C, Mahaffey K, Himmelmann A, Katus H, James S & Wallentin L (2018) Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. Thrombosis and Haemostasis, 118(02), 427-429.
Bagai A, Goodman SG, Cantor WJ, Vicaut E, Bolognese L, Cequier A, Chettibi M, Hammett CJ, Huber K, Janzon M , Lapostolle F et al (2018) Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. American Heart Journal, 196, 56-64.
Collet J-P, Roffi M, Byrne RA, Costa F, Valgimigli M, Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F , Jeppsson A et al (2018) Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. European Heart Journal, 39(3), e1-e33.
Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L , Montalescot G et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 39(3), 213-260.
Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Aukrust P, Becker RC, Bertilsson M, Himmelmann A, James SK, Siegbahn A , Storey RF et al (2018) Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. Journal of the American Heart Association, 7(2). View this article in WRRO
Magnuson EA, Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Braunwald E, Sabatine MS & Cohen DJ (2018) Reply. Journal of the American College of Cardiology, 71(1), 108-108.
Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L , Montalescot G et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.. European Journal of Cardio-thoracic Surgery, 53(1), 34-78.
Valgimigli AMDGDTM, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L , Montalescot G et al (2018) Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS. Revista Española de Cardiología, 71(1), 42.e1-42.e58.
Sumaya W & Storey RF (2018) The challenges of antithrombotic therapy in patients with left ventricular thrombosis. European Heart Journal, 39(3), 209-211.
Lip GYH, Collet JP, Caterina RD, Fauchier L, Lane DA, Larsen TB, Marin F, Morais J, Narasimhan C, Olshansky B , Pierard L et al (2017) Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). EP Europace, 19(11), 1757-1758.
Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D , Gurbel PA et al (2017) International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies. Circulation, 136(20), 1955-1975.
Patrono C, Morais J, Baigent C, Collet J-P, Fitzgerald D, Halvorsen S, Rocca B, Siegbahn A, Storey RF & Vilahur G (2017) Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology, 70(14), 1760-1776.
Cayla G, Lapostolle F, Ecollan P, Stibbe O, Benezet JF, Henry P, Hammett CJ, Lassen JF, Storey RF, ten Berg JM , Hamm CW et al (2017) Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. International Journal of Cardiology, 244, 49-53.
Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, Im KA, Murphy SA, Magnani G, Ophuis TO , Rudah M et al (2017) Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. Journal of the American College of Cardiology, 70(11), 1368-1375.
Giannitsis E, Wallentin L, James SK, Bertilsson M, Siegbahn A, Storey RF, Husted S, Cannon CP, Armstrong PW, Steg PG & Katus HA (2017) Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care, 6(6), 500-510.
Smith SA, Samokhin AO, Alfadi M, Murphy EC, Rhodes D, Kiss-Toth E, Storey RF, Yee S-P, Francis SE & Qwarnstrom EE (2017) The IL-1RI Co-Receptor TILRR (FREM1 Isoform 2) Controls Aberrant Inflammatory Responses and Development of Vascular Disease. JACC - Journal of the American College of Cardiology bts, 2(4), 398-414. View this article in WRRO
Fabris E, van ’t Hof A, Hamm CW, Lapostolle F, Lassen JF, Goodman SG, ten Berg JM, Bolognese L, Cequier A, Chettibi M , Hammett CJ et al (2017) Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. European Heart Journal: Acute Cardiovascular Care.
Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Johanson P, Bengtsson O, Himmelmann A , Braunwald E et al (2017) P3670Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal, 38(suppl_1).
Bonaca M, Jarolim P, Goodrich EL, Storey RF, Bhatt DL, Steg PG, Cohen M, Jensen E, Johanson P, Braunwald E , Morrow DA et al (2017) 2864Growth differentiation factor 15 and bleeding risk with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal, 38(suppl_1).
Magnuson EA, Li H, Wang K, Vilain K, Shafiq A, Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF , Braunwald E et al (2017) Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology, 70(5), 527-538.
Lowenstern A, Storey RF, Neely M, Sun J-L, Angiolillo DJ, Cannon CP, Himmelmann A, Huber K, James SK, Katus HA , Morais J et al (2017) Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 44(2), 145-153. View this article in WRRO
Pollack CV, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST, Schulte PJ, Spinar J, Steg PG, Storey RF , Himmelmann A et al (2017) Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.. Clin Cardiol.
Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, Torp-Pedersen C, Kjeldsen K, Lewis BS, Drexel H , Kaski JC et al (2017) Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 38(22), 1710-1716.
Fabris E, van’t Hof A, Hamm C, Lapostolle F, Lassen J, Goodman S, ten Berg J, Bolognese L, Cequier A, Chettibi M , Hammett C et al (2017) Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. EuroIntervention, 13(1), 69-77.
Gaglia MA, Lipinski MJ, Lhermusier T, Steinvil A, Kiramijyan S, Pokharel S, Torguson R, Angiolillo DJ, Wallentin L, Storey RF & Waksman R (2017) Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes Following Treatment With Ticagrelor. The American Journal of Cardiology, 119(8), 1135-1140.
Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López‐Sendón JL, Steg PG , Storey RF et al (2017) Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association, 6(4), e005580-e005580. View this article in WRRO
Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, Husted S, Storey RF, Cannon CP, Becker RC , James SK et al (2017) Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American Heart Journal, 186, 91-99.
Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF , Steg PG et al (2017) Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thrombosis and Haemostasis, 117(5), 940-947.
Gosling R, Yazdani M, Parviz Y, Hall IR, Grech ED, Gunn JP, Storey RF & Iqbal J (2017) Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients. Platelets, 28(8), 767-773. View this article in WRRO
Orme R, Judge HM & Storey RF (2017) Monitoring Antiplatelet Therapy.. Semin Thromb Hemost, 43(3), 311-319.
Storey RF, Morais JC & Rocca B (2017) Steen Elkjær Husted MD FESC 1950–2016. European Heart Journal, 38(7), 472-472.
Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A , Steg PG et al (2017) Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 63(2), 573-584.
Röshammar D, Bergstrand M, Andersson T, Storey RF & Hamrén B (2017) Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction. Int. Journal of Clinical Pharmacology and Therapeutics, 55(05), 416-424.
Greenhalgh KA, Strachan MW, Alzahrani S, Baxter PD, Standeven KF, Storey RF, Ariens RAS, Grant PJ, Price JF & Ajjan RA (2017) BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes. Thrombosis and Haemostasis, 117(2), 295-302.
Sumaya W & Storey RF (2017) Ticagrelor: Effects Beyond the P2Y12 Receptor.. Interv Cardiol Clin, 6(1), 49-55. View this article in WRRO
Parker WA, Bhatt DL, Prats J, Day JRS, Steg PG, Stone GW, Hamm CW, Mahaffey KW, Price MJ, Michael Gibson C , White HD et al (2017) Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 117(06), 1093-1100.
Parker WAE & Storey RF (2016) Ticagrelor: agonising over its mechanisms of action. Blood, 128(23), 2595-2597.
Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O'Brien R, Storey RF, Na L, Lewis SC, Thokala P & Newby DE (2016) The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) - a multicentre parallel-group randomised trial to compare early computerised tomography coronary angiography versus standard care in patients presenting with suspected or confirmed acute coronary syndrome: study protocol for a randomised controlled trial.. Trials, 17(1), 579-579. View this article in WRRO
Röshammar D, Nyberg J, Andersson T, Stanski D, Storey RF & Hamrén B (2016) Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction. The Journal of Clinical Pharmacology.
Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Aukrust P, Becker RC, Bertilsson M, Himmelmann A, James SK, Siegbahn A , Storey RF et al (2016) Abstract 12851: Osteoprotegerin is Associated With Major Bleeding but Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes - Insights From the PLATelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation, 134(suppl_1).
Halvorsen S, Storey RF, Rocca B, Sibbing D, ten Berg J, Grove EL, Weiss TW, Collet J-P, Andreotti F, Gulba DC , Lip GYH et al (2016) Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, ehw454-ehw454.
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP , Gencer B et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Giornale Italiano di Cardiologia, 17(10), 831-872.
Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Goodrich E, Mauri L, Ophuis TO, Ruda M , Špinar J et al (2016) Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation, 134(12), 861-871.
Storey RF & Parker WAE (2016) Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 134(11), 793-796. View this article in WRRO
Björquist A, Di Buduo CA, Femia EA, Storey RF, Becker RC, Balduini A, Nylander S & Cattaneo M (2016) Studies of the interaction of ticagrelor with the P2Y 13 receptor and with P2Y 13 -dependent pro-platelet formation by human megakaryocytes. Thrombosis and Haemostasis, 116(6), 1079-1088.
Li J, Tang W, Storey RF, Husted S & Teng R (2016) Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Int. Journal of Clinical Pharmacology and Therapeutics, 54(09), 666-674.
Thomas MR & Storey RF (2016) Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors. Vascular Pharmacology, 84, 25-27.
Storey RF & Sinha A (2016) Cangrelor for the management and prevention of arterial thrombosis. Expert Review of Cardiovascular Therapy, 14(9), 991-999. View this article in WRRO
Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A , Theroux P et al (2016) Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. JAMA Cardiology, 1(4), 425-425.
Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A, Neely B, Husted S, James SK, Katus HA , Lopes RD et al (2016) Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal, 177, 1-8.
Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J , Dellborg M et al (2016) Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 67(23), 2719-2728.
Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E , Sabatine MS et al (2016) Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54. Journal of the American College of Cardiology, 67(23), 2732-2740.
Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, Tsatsaris A, Baradat C, Salhi N, Hamm CW , Lapostolle F et al (2016) P2Y₁₂ receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction: The PRIVATE-ATLANTIC study. Thrombosis and Haemostasis, 116(2), 369-378.
Parker WAE & Storey RF (2016) Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart, 102(10), 783-789.
Thomas MR, Morton AC, Hossain R, Chen B, Luo L, Shahari NNBM, Hua P, Beniston RG, Judge HM & Storey RF (2016) Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thrombosis and Haemostasis, 116(1), 96-102.
Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A, Himmelmann A, Husted S, Katus HA, Meier B , Schulte PJ et al (2016) Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart, 102(8), 617-625.
Roffi M, Gencer B, Storey RF, Andreotti F & Patrono C (2016) Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines. Current Cardiology Reports, 18(5).
Montalescot G, van ’t Hof AW, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Collet J-P, Goodman SG, Hammett CJ, Huber K , Janzon M et al (2016) Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H24 Analysis. JACC: Cardiovascular Interventions, 9(7), 646-656.
de Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Collet JP, Halvorsen S, Huber K , Jespersen J et al (2016) Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 115(4), 685-711.
Johansson Å, Eriksson N, Lindholm D, Varenhorst C, James S, Syvänen A-C, Axelsson T, Siegbahn A, Barratt BJ, Becker RC , Himmelmann A et al (2016) Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Human Molecular Genetics, 25(7), 1447-1456.
Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF , Steg PG et al (2016) Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology, 67(10), 1145-1154. View this article in WRRO
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP , Gencer B et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Russian Journal of Cardiology, 131(3), 9-63.
Kaudewitz D, Skroblin P, Bender LH, Barwari T, Willeit P, Pechlaner R, Sunderland NP, Willeit K, Morton AC, Armstrong PC , Chan MV et al (2016) Association of MicroRNAs and YRNAs With Platelet FunctionNovelty and Significance. Circulation Research, 118(3), 420-432. View this article in WRRO
Lipinski MJ, Gaglia MA, Lhermusier T, Steinvil A, Kiramijyan S, Torguson R, Kim J, Chandra N, Angiolillo DJ, Wallentin L , Storey RF et al (2016) CRT-200.62 The Impact of Ticagrelor on Platelet Reactivity in African Americans: Interim Results of the ACS Ethnicity Study. JACC: Cardiovascular Interventions, 9(4), S22-S22.
Bui AH, Cannon CP, Steg PG, Storey RF, Husted S, Guo J, Im K, James SK, Michelson EL, Himmelmann A , Held C et al (2016) Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation: Arrhythmia and Electrophysiology, 9(2).
Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP , Gencer B et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 37(3), 267-315.
Roffi M & Patrono C (2016) CardioPulse: 'Ten Commandments' of 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (NSTE-ACS).. Eur Heart J, 37(3), 208.
Unverdorben M, Parodi G, Pistolesi M & Storey RF (2016) Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics. International Journal of Cardiology, 202, 167-173.
Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T, Budaj A, Goto S, López-Sendón J , Diaz R et al (2016) Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal, 37(14), 1133-1142.
Hagström E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, Katus HA, Steg PG, Storey RF, Siegbahn A & Wallentin L (2016) Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal, 37(16), 1325-1333.
Bueno H, Sinnaeve P, Annemans L, Danchin N, Licour M, Medina J, Pocock S, Sánchez-Covisa J, Storey RF, Jukema JW , Zeymer U et al (2016) Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. European Heart Journal: Acute Cardiovascular Care, 5(1), 3-12.
Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP , Gencer B et al (2015) 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Española de Cardiología (English Edition), 68(12), 1125-1125.
Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP , Gencer B et al (2015) Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología, 68(12), 1125.e1-1125.e64.
Thomas MR, Outteridge SN, Ajjan RA, Phoenix F, Sangha GK, Faulkner RE, Ecob R, Judge HM, Khan H, West LE , Dockrell DH et al (2015) Platelet P2Y 12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 35(12), 2562-2570. View this article in WRRO
Murphy SA, Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Deenadayalu N, Kuder JF, Magnani G, Theroux P , Nicolau JC et al (2015) Abstract 17121: Reduction in Total Cardiovascular Events With Long-term Use of Ticagrelor in Patients With Prior Myocardial Infarction in the PEGASUS-TIMI 54 Trial. Circulation, 132(suppl_3).
Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Husted S, Katus HA, Maurer G, Lopez-Sendon J , Steg PG et al (2015) Abstract 13290: GDF-15 at One Month After an Acute Coronary Syndrome is Associated With Increased Risk of Major Bleeding - A PLATO Biomarker Substudy. Circulation, 132(suppl_3).
Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Kuder J, Murphy SA, Magnani G , Budaj A et al (2015) Abstract 11594: Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. Circulation, 132(suppl_3).
Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Im K, Magnani G, Oude Ophuis T, Ruda M, Parkhomenko A , Isaza D et al (2015) Abstract 19642: Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54. Circulation, 132(suppl_3).
Kaier K, Gutmann A, Vach W, Sorg S, Siepe M, von zur Mühlen C, Moser M, Blanke P, Beyersdorf F, Zehender M , Bode C et al (2015) “Heart Team” decision making in elderly patients with symptomatic aortic valve stenosis who underwent AVR or TAVI – a look behind the curtain. Results of the prospective TAVI Calculation of Costs Trial (TCCT). EuroIntervention, 11(8), 793-798.
Ducrocq G, Schulte PJ, Becker RC, Cannon CP, Harrington RA, Held C, Himmelmann A, Lassila R, Storey RF, Sorbets E , Wallentin L et al (2015) Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention, 11(8), 737-745.
Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg PG , Storey RF et al (2015) Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: An analysis from the platelet inhibition and patient outcomes (PLATO) trial. Journal of the American Heart Association, 4(10). View this article in WRRO
Storey R & Thomas M (2015) The role of platelets in inflammation. Thrombosis and Haemostasis, 114(09), 449-458.
Judge HM, Buckland R, Jakubowski JA & Storey RF (2015) Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y 12 receptors in vitro. Platelets, 27(3), 191-195. View this article in WRRO
Alsharif KF, Thomas MR, Judge HM, Khan H, Prince LR, Sabroe I, Ridger VC & Storey RF (2015) Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis. Vascular Pharmacology, 71, 201-207. View this article in WRRO
Storey R & Thomas M (2015) Effect of P2Y12 inhibitors on inflammation and immunity. Thrombosis and Haemostasis, 114(09), 490-497.
Thomas MR & Storey RF (2015) The future of P2Y12receptor antagonists. Platelets, 26(5), 392-398.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K , Bengtsson O et al (2015) Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 372(19), 1791-1800.
Storey RF (2015) More transparency for a therapeutic window in platelet P2Y12inhibition?. European Heart Journal, 36(27), 1714-1717.
Varenhorst C, Eriksson N, Johansson Å, Barratt BJ, Hagström E, Åkerblom A, Syvänen A-C, Becker RC, James SK, Katus HA , Husted S et al (2015) Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal, 36(29), 1901-1912.
Sumaya W, Joshi RR, Judge HM, Ecob R, Morton AC & Storey RF (2015) Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min period.. Platelets, 26(3), 271-273.
Kholaif N, Zheng Y, Jagasia P, Himmelmann A, James SK, Steg PG, Storey RF, Westerhout CM & Armstrong PW (2015) Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex. The American Journal of Medicine, 128(8), 914.e11-914.e19.
Lindholm D, Storey RF, Christersson C, Halvorsen S, Grove EL, Braun OÖ, Varenhorst C & James SK (2015) Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. American Heart Journal, 170(3), 465-470.
Johansson Å, Eriksson N, Becker RC, Storey RF, Himmelmann A, Hagström E, Varenhorst C, Axelsson T, Barratt BJ, James SK , Katus HA et al (2015) NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Genetics, 8(3), 498-506.
Velders MA, Wallentin L, Becker RC, van Boven AJ, Himmelmann A, Husted S, Katus HA, Lindholm D, Morais J, Siegbahn A , Storey RF et al (2015) Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. American Heart Journal, 169(6), 879-889.e7.
Dewilde WJM, Janssen PWA, Verheugt FWA, Storey RF, Adriaenssens T, Hansen ML, Lamberts M & ten Berg JM (2015) Reply. Journal of the American College of Cardiology, 65(5), 516-518.
Collet J-P, Mair J, Plebani M, Merkely B, Jaffe AS, Möckel M, Giannitsis E, Thygesen K, ten Berg JM, Mueller C , Storey RF et al (2015) Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding?. Thrombosis and Haemostasis, 113(02), 221-230.
Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K & Siller-Matula JM (2015) How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?. Thrombosis and Haemostasis, 113(01), 37-52.
Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP , Gencer B et al (2015) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Kardiologia Polska, 1207-1294.
Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K & Siller-Matula JM (2015) How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?. Thrombosis and Haemostasis, 113(01), 37-52.
Newby DE, Mannucci PM, Tell GS, Baccarelli AA, Brook RD, Donaldson K, Forastiere F, Franchini M, Franco OH, Graham I , Hoek G et al (2015) Expert position paper on air pollution and cardiovascular disease. European Heart Journal, 36(2), 83-93.
Parodi G & Storey RF (2015) Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. European Heart Journal: Acute Cardiovascular Care, 4(6), 555-560.
Janzon M, James S, Cannon CP, Storey RF, Mellström C, Nicolau JC, Wallentin L & Henriksson M (2015) Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart, 101(2), 119-125.
Sinnaeve PR, Zeymer U, Bueno H, Danchin N, Medina J, Sánchez-Covisa J, Licour M, Annemans L, Jukema JW, Pocock S , Storey RF et al (2015) Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study. European Heart Journal: Acute Cardiovascular Care, 4(3), 254-262.
Judge HM, Jennings LK, Moliterno DJ, Hord E, Ecob R, Tricoci P, Rorick T, Kotha J & Storey RF (2015) PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. Platelets, 26(3), 236-242.
Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF , Wallentin L et al (2015) Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology, 22(6), 734-742.
(2014) Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 371(24), 2337-2339.
Montone RA, Hoole SP & West NEJ (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction.. N Engl J Med, 371(24), 2338-2339.
Lip GYH, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M , Zeymer U et al (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). European Heart Journal, 35(45), 3155-3179.
Iqbal J, Rowe R, Zhang Y-J, Parviz Y, Morton AC, Grech E, Gunn JP & Storey RF (2014) Abstract 20470: Lower Mortality and Stent Thrombosis Rates Associated With Introduction of Potent P2Y12 Inhibitors in Patients With Acute Coronary Syndromes. Circulation, 130(suppl_2).
Mayr M, Kaudewitz D, Skroblin P, Willeit P, Zampetaki A, Morton AC & Storey RF (2014) Abstract 20657: Plasma MicroRNAs Correlate With Platelet Reactivity in Patients With Acute Coronary Syndrome: Association With Platelet Function. Circulation, 130(suppl_2).
Dewilde WJM, Janssen PWA, Verheugt FWA, Storey RF, Adriaenssens T, Hansen ML, Lamberts M & ten Berg JM (2014) Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 64(12), 1270-1280.
Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier Á, Chettibi M, Goodman SG , Hammett CJ et al (2014) Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 371(11), 1016-1027.
Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF , Stevens SR et al (2014) Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal, 35(31), 2083-2093.
Saraf K, Morris P, Garg P, Sheridan P & Storey R (2014) Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Postgraduate Medical Journal, 90(1067), 520-528.
Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HA, Mahaffey KM, Pieper KS , Storey RF et al (2014) No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014.. Int J Cardiol, 176(1), 300-302.
Varenhorst C, Alström U, Braun OÖ, Storey RF, Mahaffey KW, Bertilsson M, Cannon CP, Scirica BM, Himmelmann A, James SK , Wallentin L et al (2014) Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.. Heart, 100(22), 1762-1769.
Sousa-Uva M, Storey R, Huber K, Falk V, Leite-Moreira AF, Amour J, Attar NA, Ascione R, Taggart D & Collet J-P (2014) Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. European Heart Journal, 35(23), 1510-1514.
Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R , Morais J et al (2014) The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.. Eur Heart J, 35(23), 1541-1550.
Thomas M, Judge H, Dockrell D, Sabroe I & Storey R (2014) 215 Ticagrelor Inhibits Release of Pro-inflammatory Cytokines TNF and IL-6 during Human Endotoxaemia. Heart, 100(Suppl 3), A117.3-A118.
Storey RF (2014) Beware the normal angiogram.. Clin Med (Lond), 14(3), 323-324.
Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G , Wallentin L et al (2014) Response to Letter Regarding Article, "Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial". CIRCULATION, 129(19), E494-E495.
Wallentin L, Himmelmann A, Storey RF, Steg PG & Harrington RA (2014) Utilisation of novel anti-platelet agents: Evidence, guidelines and proven patients' value. Thrombosis and Haemostasis, 112(1), 12-14.
Husted S, de Caterina R, Andreotti F, Arnesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip GYH, Morais J , Rasmussen LH et al (2014) Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. THROMBOSIS AND HAEMOSTASIS, 111(5), 781-782.
Alexopoulos D, Xanthopoulou I, Storey RF, Bliden KP, Tantry US, Angiolillo DJ & Gurbel PA (2014) Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis. American Heart Journal, 168(4), 530-536.
Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC, Storey RF , Ruzyllo W et al (2014) Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).. J Am Coll Cardiol, 63(11), 1048-1057.
Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S, Steg PG, Cannon CP, Becker RC, Storey RF , Khurmi NS et al (2014) Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.. J Am Coll Cardiol, 63(15), 1493-1499.
West LE, Steiner T, Judge HM, Francis SE & Storey RF (2014) Vessel wall, not platelet, P2Y12 potentiates early atherogenesis.. Cardiovasc Res, 102(3), 429-435.
Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA , Held C et al (2014) Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.. Circulation, 129(3), 293-303.
Storey R, Kristensen S & Grove E (2014) Can we improve the efficacy of low-dose aspirin?. Thrombosis and Haemostasis, 112(12), 1077-1078.
Åkerblom A, Eriksson N, Wallentin L, Johansson A, James SK, Siegbahn A, Barratt BJ, Becker RC, Budaj A, Himmelmann A , Husted S et al (2014) Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. American Heart Journal.
Storey RF, Kotha J, Smyth SS, Moliterno DJ, Rorick TL, Moccetti T, Valgimigli M, Dery JP, Cornel JH, Thomas GS , Huber K et al (2014) Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes: The TRACER pharmacodynamic substudy. Thrombosis and Haemostasis, 111(5), 883-891.
Thomas MR & Storey RF (2014) Genetics of response to antiplatelet therapy.. Prog Mol Biol Transl Sci, 124, 123-153.
Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP & Huber K (2014) Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 35(4).
Bonaca MP, Bhatt DL, Braunwald E, Sabatine MS, Cohen M, Steg PG, Storey RF, Held P & Jensen EC (2014) Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal.
Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, Moliterno DJ , Van de Werf F et al (2014) Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).. Am J Cardiol, 113(6), 936-944.
Thomas MR & Storey RF (2014) Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.. J Cardiovasc Transl Res, 7(1), 19-28.
Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, Husted SE, Cannon CP, Becker RC, Steg PG , Åsenblad N et al (2014) Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.. Platelets, 25(7), 517-525.
Joshi RR, Hossain R, Morton AC, Ecob R, Judge HM, Wales C, Walker JV, Karunakaran A & Storey RF (2014) Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.. Platelets, 25(6), 416-422.
Kaudewitz D, Lee R, Willeit P, Zampetaki A, Morton AC, Warner TD, Storey RF, Channon K & Mayr M (2013) Abstract 18427: Impact of Medication on Quantification of Plasma MicroRNAs in Patients With Cardiovascular Disease. Circulation, 128(suppl_22).
Storey RF, Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC , Ruzyllo W et al (2013) Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis from the TRACER Trial.. J Am Coll Cardiol..
Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF & Huber K (2013) Response variability to P2Y12 receptor inhibitors: Expectations and reality. JACC: Cardiovascular Interventions, 6(11), 1111-1128.
Storey RF, Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E , Harrington RA et al (2013) Biomarkers in Relation to the Effects of Ticagrelor Compared with Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with or without In-Hospital Revascularization: A Substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial.. Circulation.
Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G , Wallentin L et al (2013) Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.. Circulation, 128(10), 1055-1065.
Åkerblom A, Wallentin L, Larsson A, Siegbahn A, Becker RC, Budaj A, Himmelmann A, Horrow J, Husted S, Storey RF , Åsenblad N et al (2013) Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: Results from the PLATelet inhibition and patient outcomes (PLATO) study. Clinical Chemistry, 59(9), 1369-1375.
Hess KA, Kurdee Z, Oxley N, Phoenix F, Marx N, King R, Storey RF, Grant PJ & Ajjan RA (2013) Modulation of complement C3 levels and fibrin clot structure: the role of aspirin dose. European Heart Journal, 34(suppl 1), P4881-P4881.
Wallentin LC, Bertilsson M, Becker RC, Himmelmann A, Husted S, James S, Katus H, Steg G, Storey RF & Siegbahn A (2013) GDF-15 level in acute coronary syndrome and its relations to cardiovascular risk factors, disease manifestations, treatments and outcome - results from the PLATO-study. European Heart Journal, 34(suppl 1), P4048-P4048.
James S, Storey RF, Cannon C, Janzon M, Nicolau JC, Parasuraman B, Mellstrom K, Wallentin L & Henriksson M (2013) Health economic evaluation of ticagrelor compared to generic clopidogrel in patients with acute coronary syndromes intended for non-invasive management based on the PLATO trial. European Heart Journal, 34(suppl 1), P4901-P4901.
Varenhorst C, Alstrom U, Braun OO, Storey RF, Mahaffey KW, Cannon C, Himmelmann A, James S, Wallentin L & Held C (2013) Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial. European Heart Journal, 34(suppl 1), 4536-4536.
Storey RF, Ardissino D, Vignali L, Cairns R, Becker RC, Cannon CP, Himmelmann A, Husted S, James SK & Wallentin L (2013) Ischaemic events following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. European Heart Journal, 34(suppl 1), 4533-4533.
Judge MH, Jennings L, Moliterno D, Hord E, Ecob R, Tricoci P, Smyth S, Rorick T, Kotha J & Storey RF (2013) PAR-1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 444-444.
Kurdee Z, Mamaniat A, Phonix F, Rice P, Storey R, Grant PJ & Ajjan R (2013) Diabetes modulates the fibrinolytic properties of aspirin without altering the platelet inhibitory actions: a possible mechanism for aspirin treatment failure. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 760-760.
Bright R, Storey R & Chico T (2013) Zebrafish as a model to investigate the effect of P2Y12 knockdown on leukocyte migration. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 450-450.
West LE, Steiner T, Francis SE & Storey RF (2013) The role of vessel wall P2Y12 in early atherogenesis is not blocked by ticagrelor or clopidogrel. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 156-156.
Joshi R, Hossain R, Morton AC, Ecob R, Judge H, Wales C, Karunakaran A & Storey RF (2013) Evolving pattern of platelet P2Y12 inhibition during maintenance therapy in acute coronary syndrome patients. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 494-494.
Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J , Maya J et al (2013) Angiographic outcomes in the PLATO trial (Platelet inhibition and patient outcomes). JACC: Cardiovascular Interventions, 6(7), 671-683.
Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GYH, Verheugt FWA, Huber K, Grove EL, Morais J, Husted S , Wassmann S et al (2013) Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. EUROPEAN HEART JOURNAL, 34(23), 1708-+.
Iqbal J, Sumaya W, Tatman V, Parviz Y, Morton AC, Grech ED, Campbell S, Storey RF & Gunn J (2013) Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting.. EuroIntervention, 9(1), 62-69.
James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, Wallentin L & Harrington RA (2013) Ticagrelor in patients with acute coronary syndromes and stroke: Interpretation of subgroups in clinical trials. Stroke, 44(5), 1477-1479.
Storey RF (2013) Antiplatelet therapy: Cangrelor succeeds, at last, in PCI. Nature Reviews Cardiology, 10(6), 302-304.
Grove EL, Hossain R & Storey RF (2013) Platelet function testing and prediction of procedural bleeding risk.. Thromb Haemost, 109(5).
Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC , Oto A et al (2013) Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation, 127(6), 673-680.
Sumaya W, Daly RL, Mehra S, Dhutia AJ, Howgego KE, Ecob R, Judge HM, Morton AC & Storey RF (2013) Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay.. Thromb Haemost, 109(3), 550-555.
Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P , Erdine S et al (2013) ESC/EAS Guidelines for the Management of Dyslipidaemias. Revista Portuguesa de Cardiologia (English Edition), 32(1), 83-84.
Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P , Erdine S et al (2013) ESC/EAS Guidelines for the Management of Dyslipidaemias. Revista Portuguesa de Cardiologia (English Edition), 32(1), 81-82.
Storey RF, Wallentin L, James S, Giannitsis E, Katus H, Becker RC, Cannon CP, Horrow J, Husted S, Siegbahn A & Steg GP (2013) Outcomes with ticagrelor versus clopidogrel in relation to high sensitivity troponin-T in non-ST-elevation acute coronary syndrome patients managed with early invasive or non-invasive treatment: a substudy from the prospective randomized PLATelet inhibit.. Pharmacotherapy(33), E189-E189.
Wallentin L, Held C, James SK, Becker RC, Pieper KS, Cannon CP, Himmelmann A, Husted S, Katus HS, Mahaffey KW , Harrington RA et al (2013) Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial, International Journal of Cardiology,. International Journal of Cardiology.
Amoah V, Storey RF, Worrall AP, Goodridge K, Lovatt T, Smallwood A, Armesilla AL, Nevill AM & Cotton JM (2013) Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes. PLATELETS, 24(8), 643-648.
Kaudewitz D, Lee R, Willeit P, McGregor R, Markus HS, Kiechl S, Zampetaki A, Storey RF, Channon KM & Mayr M (2013) Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thrombosis and Haemostasis, 110(3), 609-615.
Armstrong PW, Westerhout CM, Fu Y, Harrington RA, Storey RF, Katus H, James S & Wallentin L (2013) Quantitative ST-depression in acute coronary syndromes: The plato electrocardiographic substudy. American Journal of Medicine, 126(8).
Levin LA, Wallentin L, Bernfort L, Andersson D, Storey RF, Bergström G, Lamm CJ, Janzon M & Kaul P (2013) Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes - Results from the PLATO Trial. Value in Health, 16(4), 574-580.
Bueno H, Storey RF, Danchin N, Sanchez-Coviza J, Licours M, Annemans L, Jukema JW, Zeymers U & Van de Werf F (2012) An International Perspective of Current Patterns of Antiplatelet Drug Use in Acute Coronary Syndrome Patients. Results from the EPICOR Study. CIRCULATION, 126(21).
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR & White HD (2012) Third universal definition of myocardial infarction. Nature Reviews Cardiology, 9(11), 620-633.
Grove EL, Storey RF & Wurtz M (2012) Platelet Function Testing in Atherothrombotic Disease. CURRENT PHARMACEUTICAL DESIGN, 18(33), 5379-5391.
(2012) 'Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial' [Eur Heart J 2011; 32:2933-2944, doi:10.1093/eurheartj/ehr422. R.C. Becker, J.P. Bassand, A. Budaj, D.M. Wojdyla, S.K. James, J.H. Cornel, J. French, C. Held, J. Horrow, S. Husted, J. Lopez-Sendon, R. Lassila, K.W. Mahaffey, R.F. Storey, R.A. Harrington, L. Wallentin. European Heart Journal, 33(21), 2750-2750.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS , Katus HA et al (2012) Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 60(16), 1581-1598.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR & White HD (2012) Third Universal Definition of Myocardial Infarction. Circulation, 126(16), 2020-2035.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS , Katus HA et al (2012) Third universal definition of myocardial infarction. European Heart Journal, 33(20), 2551-2567.
Goodman SG, Clare R, Pieper KS, Mahaffey KW, Harrington RA, Nicolau JC, Storey RF, Cantor WJ, Angiolillo DJ, Husted S , Cannon CP et al (2012) Response to Letter Regarding Article, "Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO". CIRCULATION, 126(11), E171-E172.
Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J , Mahaffey KW et al (2012) Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 5(5), 680-688.
Ahmad S & Storey RF (2012) Development and clinical use of prasugrel and ticagrelor.. Curr Pharm Des, 18(33), 5240-5260.
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K , Ohman M et al (2012) ESC guidelines for the treatment of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Giornale Italiano di Cardiologia, 13(3), 171-228.
Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K , Ohman M et al (2012) ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Revista Española de Cardiología (English Edition), 65(2), 173-173.
Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K , Ohman M et al (2012) Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología, 65(2), 173.e1-173.e55.
Karunakaran A, Sumaya W, Gunn JP, Morton AC & Storey RF (2012) Contemporary management of ST-segment elevation myocardial infarction.. Hosp Pract (1995), 40(1), 224-231.
Åkerblom A, Wallentin L, Åsenblad N, James SK, Åkerblom A, Wallentin L, James SK, Siegbahn A, Becker RC, Budaj A , Horrow J et al (2012) Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients-Results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal.
Varenhorst C, Åsenblad N, James S, Wallentin L, Held C, Alström U, Scirica BM, Cannon CP, Hogue CW, Storey RF , Steg PHG et al (2012) Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology.
James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, Maya J, Morais J, Lopes RD, Nicolau JC , Pais P et al (2012) Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation, 125(23), 2914-2921.
Siha H, Das D, Fu Y, Zheng Y, Westerhout CM, Storey RF, James S, Wallentin L & Armstrong PW (2012) Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: Insights from the PLATO trial. CMAJ, 184(10), 1135-1142.
Cornel JH, Becker RC, Goodman SG, Husted S, Katus H, Santoso A, Steg G, Storey RF, Vintila M, Sun JL , Horrow J et al (2012) Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal.
Husted SE, Storey RF, Bliden K, Tantry US, Høimark L, Butler K, Wei C, Teng R & Gurbel PA (2012) Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: Results from the ONSET-OFFSET and RESPOND studies. Clinical Pharmacokinetics, 51(6), 397-409.
Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, Mahaffey KW, Angiolillo DJ, Husted S, Cannon CP , James SK et al (2012) Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: Insights from the platelet inhibition and patient outcomes trial. Circulation, 125(8), 978-986.
Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van De Werf F, White HD, Aylward PE, Wallentin L, Chen E , Lokhnygina Y et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. New England Journal of Medicine, 366(1), 20-33.
Armstrong PW, Siha H, Fu Y, Westerhout CM, Steg PG, James SK, Storey RF, Horrow J, Katus H, Clemmensen P , Harrington RA et al (2012) ST-elevation acute coronary syndromes in the platelet inhibition and patient outcomes (PLATO) trial: Insights from the ECG substudy. Circulation, 125(3), 514-521.
Storey RF (2012) Republished education in heart: New P2Y₁₂ inhibitors.. Postgrad Med J, 88(1035), 49-54.
Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, Giannitsis E, Horrow J, Husted S, Katus HA , Steg PG et al (2012) Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with ST-Elevation and Non-ST-Elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes Study. CLINICAL CHEMISTRY, 58(1), 190-199.
Thomas MR & Storey RF (2012) Optimal management of antiplatelet therapy and proton pump inhibition following percutaneous coronary intervention.. Curr Treat Options Cardiovasc Med, 14(1), 24-38.
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K , Ohman M et al (2011) Wytyczne dotycza̧ce diagnostyki i leczenia ostrych zespołów wieńcowych bez przetrwałego uniesienia odcinka ST. Kardiologia Polska, 69(SUPPL. 5).
Armstrong PW, Siha H, Fu Y, Westerhout CM, Steg PG, James SK, Storey RF, Horrow J, Katus H, Clemmensen P , Harrington RA et al (2011) ST Elevation Acute Coronary Syndromes in PLATO. Circulation, 1-1.
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P , Erdine S et al (2011) Wytyczne ESC/EAS dotycza̧ce postêpowania w dyslipidemiach. Kardiologia Polska, 69(SUPPL. 4).
Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O, Agewall S, Alegría E, John Chapman M, Durrington P , Erdine S et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Revista Española de Cardiología (English Edition), 64(12), 1168-1168.
Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K , Ohman M et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 32(23), 2999-3054.
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K , Ohman M et al (2011) Israrci ST-segment yükselmesi belirtileri göstermeyen hastalarda Akut KoronerSendromlarin (AKS) tedavi kilavuzlari. Turk Kardiyoloji Dernegi Arsivi, 39(SUPP -3), 73-128.
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P , Erdine S et al (2011) ESC/EAS Kilavuzlari: Dislipidemilerin tedavisi. Turk Kardiyoloji Dernegi Arsivi, 39(SUPP -3), 5-72.
Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O, Agewall S, Alegría E, John Chapman M, Durrington P , Erdine S et al (2011) Guía de la ESC/EAS sobre el manejo de las dislipemias. Revista Española de Cardiología, 64(12), 1168.e1-1168.e60.
Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt W, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF , Wallentin L et al (2011) Cardiovascular Events in Acute Coronary Syndrome Patients With Peripheral Arterial Disease Treated With Ticagrelor Compared to Clopidogrel: Data From the PLATO Trial. CIRCULATION, 124(21).
James SK, Storey RF, Bushnell C, Horrow J, Husted S, Mahaffey KW, Maya J & Becker RC (2011) Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndromes and History of Stroke or Transient Ischemic Accident: Results from the Platelet Inhibition and Patient Outcomes Trial. CIRCULATION, 124(21).
Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Lim ST , Cannon CP et al (2011) Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).. Am J Cardiol, 108(11), 1542-1546.
Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS , Horrow J et al (2011) Ticagrelor Compared with Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, 124(5), 660-660.
Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS , Horrow J et al (2011) Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, 124(5), 544-U78.
Akerblom A, Wallentin L, Siegbahn A, Budaj A, Horrow J, Husted S, Steg GP, Storey R, Asenblad N & James S (2011) Serial renal function assessment with cystatin c in patients with acute coronary syndrome randomized to ticagrelor or clopidogrel. EUROPEAN HEART JOURNAL, 32, 417-417.
Steg PG, Harrington RA, Storey R, Emanuelsson H, Katus H, Mahaffey K, Meir B, Wojdyla D, Wallentin L & James S (2011) Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention -an analysis from the prospective randomized PLATO trial. EUROPEAN HEART JOURNAL, 32, 415-416.
Storey RF (2011) New P2Y(12) inhibitors. HEART, 97(15), 1262-1267.
Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A , Cairns R et al (2011) Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.. Eur Heart J, 32(23), 2945-2953.
Catapano AL, Reiner Ž, De Backer G, Graham I, Taskinen M-R, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P , Erdine S et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 217, 1-44.
Catapano AL, Reiner Ž, De Backer G, Graham I, Taskinen M-R, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P , Erdine S et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 217(1), 3-46.
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P , Erdine S et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 32(14), 1769-1818.
Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, Wei C, Tantry U & Gurbel PA (2011) Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.. J Thromb Haemost, 9(9), 1730-1737.
James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF , Stevens S et al (2011) Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BRIT MED J, 342. View this article in WRRO
Badimon L, Storey RF & Vilahur G (2011) Update on lipids, inflammation and atherothrombosis. THROMB HAEMOSTASIS, 105, S34-S42.
Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D , Spinar J et al (2011) The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial Results of the Continuous Electrocardiographic Assessment Substudy. J AM COLL CARDIOL, 57(19), 1908-1916.
Storey RF (2011) Education in atherothrombosis.. Thromb Haemost, 105 Suppl 1, S1-S2.
Storey RF (2011) Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.. Thromb Haemost, 105 Suppl 1, S75-S81.
Storey RF (2011) Exploring mechanisms of graft occlusion toward improved outcomes in coronary artery bypass graft surgery.. J Am Coll Cardiol, 57(9), 1078-1080.
Shand JA, Menown IBA & Storey RF (2011) Ticagrelor: from concept to clinical evaluation.. Biomark Med, 5(1), 53-62.
Thomas MR & Storey RF (2011) Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention. Current Treatment Options in Cardiovascular Medicine, 1-15.
Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S , Lopez-Sendon J et al (2011) Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial. European Heart Journal, 32(23), 2933-2944.
Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, De Caterina R, Gulba D, Huber K, Husted S , Kristensen SD et al (2011) Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal, 32(23), 2922-2932.
Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Lim ST , Cannon CP et al (2011) Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the platelet inhibition and patient outcomes [PLATO] pulmonary function substudy). American Journal of Cardiology, 108(11), 1542-1546.
Bliden KP, Tantry US, Storey RF, Jeong Y-H, Gesheff M, Wei C & Gurbel PA (2011) The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. American Heart Journal.
Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK , Mahaffey KW et al (2011) Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.. J Am Coll Cardiol, 57(6), 672-684.
Patil SB, Jackman LE, Francis SE, Judge HM, Nylander S & Storey RF (2010) Sustained P2Y12 Receptor Inhibition is Required to Effectively Inhibit Neointima Formation in a Murine Vascular Injury Model. CIRCULATION, 122(21).
Gurbel PA, Bliden K, Storey RF, Wei C, Armstrong M, Butler K & Tantry US (2010) First Analysis of Relation Between CYP2C19 Genotype and Platelet Function in Ticagrelor versus Clopidogrel Treated Patients: Results from the ONSET/OFFSET and RESPOND Studies. CIRCULATION, 122(21).
Storey RF, Angiolillo DJ & Patil SB (2010) Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy (vol 56, pg 1456, 2010). J AM COLL CARDIOL, 56(22), 1895-1895.
Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K & Gurbel PA (2010) First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.. Circ Cardiovasc Genet, 3(6), 556-566.
Patil SB, Jackman LE, Francis SE, Judge HM, Nylander S & Storey RF (2010) Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.. Arterioscler Thromb Vasc Biol, 30(12), 2385-2391.
Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H , Kilhamn J et al (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.. Circulation, 122(21), 2131-2141.
Randall M, Storey RF, Venables GS, Gaines PA & Cleveland TJ (2010) POS10 Variability in patient response to clopidogrel and effects on outcome from carotid stenting.. J Neurol Neurosurg Psychiatry, 81(11), e69-e70.
Storey RF (2010) What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus?. Diab Vasc Dis Res, 7(4), 249-250.
James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M , Lewis BS et al (2010) Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, 122(11), 1056-1067.
Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC & Wallentin L (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.. J Am Coll Cardiol, 56(18), 1456-1462.
James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF , Stevens SR et al (2010) Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.. Eur Heart J, 31(24), 3006-3016.
Geisler T, Gawaz M, Steinhubl SR, Bhatt DL, Storey RF & Flather M (2010) Current strategies in antiplatelet therapy - Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. PHARMACOL THERAPEUT, 127(2), 95-107.
Storey RF, Bliden KP, Patil SB, Karunakaran A, Ecob R, Butler K, Teng R, Wei C, Tantry US, Gurbel PA & ONSET/OFFSET Investigators (2010) Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.. J Am Coll Cardiol, 56(3), 185-193.
Judge HM, Patil SB, Buckland RJ, Jakubowski JA & Storey RF (2010) Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.. J Thromb Haemost, 8(8), 1820-1827.
Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA & Storey RF (2010) Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function.. Thromb Haemost, 103(6), 1210-1217.
Nergiz-Unal R, Cosemans JMEM, Feijge MAH, van der Meijden PEJ, Storey RF, van Giezen JJJ, Egbrink MGAO, Heemskerk JWM & Kuijpers MJE (2010) Stabilizing Role of Platelet P2Y(12) Receptors in Shear-Dependent Thrombus Formation on Ruptured Plaques. PLOS ONE, 5(4). View this article in WRRO
Husted S, Storey RF, Harrington RA, Emanuelsson H & Cannon CP (2010) Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel. CLIN CARDIOL, 33(4), 206-212.
Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng RL, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW , Sabe-Affaki G et al (2010) Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies The RESPOND Study. CIRCULATION, 121(10), 1188-1199.
Storey RF, Becker RC, Cannon CP, Cools F, Emanuelsson H, Harrington RA, Husted S, James S, Katus H, Nardev K , Lim ST et al (2010) TICAGRELOR DOES NOT AFFECT PULMONARY FUNCTION TESTS COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROMES: RESULTS OF THE PLATO PULMONARY SUBSTUDY. Journal of the American College of Cardiology, 55(10), A108.E1007-A108.E1007.
Scirica BM, Cannon CP, Emanuelsson H, Harrington RA, Husted S, James SK, Katus H, Michelson EL, Prem P, Dmitar R , Spinar J et al (2010) THE INCIDENCE OF ARRHYTHMIAS AND CLINICAL ARRHYTHMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH TICAGRELOR OR CLOPIDOGREL IN THE PLATO TRIAL. Journal of the American College of Cardiology, 55(10), A108.E1006-A108.E1006.
Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS , Kontny F et al (2010) Comparison of ticagrelor with clopidogrel in patients with planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. LANCET, 375(9711), 283-293.
Geisler T, Gawaz M, Steinhubl SR, Bhatt DL, Storey RF & Flather M (2010) Erratum to Current strategies in antiplatelet therapy - Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease? [Pharmacol. Ther., 127(2), (2010), 95-107]. Pharmacology and Therapeutics, 128(2), 385.
Buch MH, Prendergast BD & Storey RF (2010) Antiplatelet therapy and vascular disease: An update. Therapeutic Advances in Cardiovascular Disease, 4(4), 249-275.
Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH & Becker RC (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. The Lancet.
Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A , Kereiakes DJ et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.. Circulation, 120(25), 2577-2585.
Grove EL & Storey RF (2009) The right oral antithrombotics in acute coronary syndromes. LANCET, 374(9706), 1947-1948.
Lopez-Sendon JL & Storey RF (2009) Antiplatelet therapy for acute coronary syndrome treated with percutaneous coronary intervention: New Developments Conclusions. EUR HEART J SUPPL, 11(G), G25-G26.
Lopez-Sendon JL & Storey RF (2009) Antiplatelet therapy for acute coronary syndrome treated with percutaneous coronary intervention: New Developments Introduction. EUR HEART J SUPPL, 11(G), G2-G3.
Storey RF, Bliden K, Patil SB, Karunakaran A, Ecob R, Butler K, Teng R & Gurbel P (2009) Abstract 5768: The Effect of Ticagrelor on Cardiopulmonary Function in Patients With Stable Coronary Artery Disease. Circulation, 120(suppl_18).
Gurbel P, Bliden K, Butler K, Tantry U, Teng R, Antonino M, Patil SB, Karunakaran A, Kereiakes D, Paris C , Rsch D et al (2009) Abstract 5762: A Randomized Double-Blind Study to Assess the Onset and Offset of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients With Stable Coronary Artery Disease. Circulation, 120(suppl_18).
Storey RF, Patil SB, Ecob R, Angiolillo DJ & Wallentin L (2009) Abstract 5495: More Rapid and Consistent Inhibition of Platelet Aggregation is Achieved by Loading With Ticagrelor Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy. Circulation, 120(suppl_18).
Husted SE, Gurbel P, Storey RF, Bliden K, Høimark L, Antonino MJ, Mahla E, Tantry U, Butler K, Wei C & Teng R (2009) Abstract 5494: Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Coronary Artery Disease. Circulation, 120(suppl_18).
Storey RF, Angiolillo DJ, Patil SB, Desai B, Husted S, Emanuelsson H & Wallentin L (2009) Abstract 4947: Maintenance Treatment With Ticagrelor Yields Greater and More Consistent Inhibition of Platelet Function Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy. Circulation, 120(suppl_18).
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H , Mahaffey KW et al (2009) Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. NEW ENGL J MED, 361(11), 1045-1057.
Buckland R, Judge HM, Sugidachi A, Jakubowski JA & Storey RF (2009) Cangrelor inhibits the binding of clopidogrel and prasugrel active metabolites to the P2Y12 receptor. EUROPEAN HEART JOURNAL, 30, 193-193.
Harrington RA, Van de Werf F, Armstrong PW, Aylward P, Veltri E, Mahaffey KW, Moliterno DJ, Strony J, Wallentin L, White HD , Diaz R et al (2009) The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale. AM HEART J, 158(3), 327-U5.
Storey RF, Melissa Thornton S, Lawrance R, Husted S, Wickens M, Emanuelsson H, Cannon CP, Heptinstall S & Armstrong M (2009) Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.. Platelets, 20(5), 341-348.
James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R , Becker R et al (2009) Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. AM HEART J, 157(4), 599-605.
Husted S, Harrington RA, Cannon CP, Storey RF, Mitchell P & Emanuelsson H (2009) Bleeding risk with AZD6140, a reversible P2Y(12) receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. INT J CLIN PRACT, 63(4), 667-670.
Storey RF (2009) Platelet Physiology and the Role of the Platelet in Ischemic Heart Disease, 1-14.
Storey RF (2009) Clopidogrel in acute coronary syndrome: to genotype or not?. Lancet, 373(9660), 276-278.
Evans DJW, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K, Norman KE, Francis SE & Storey RF (2009) Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis.. Circulation, 119(1), 116-122.
Storey RF, Cannon CP, Harrington RA, Sandset PM, Heptinstall S, Wickens M, Peters G, Emanuelsson H & Husted S (2008) Final aggregation response is a more sensitive marker of the effects of P2Y12 receptor antagonists than maximal aggregation response. EUROPEAN HEART JOURNAL, 29, 405-405.
Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA & Storey RF (2008) Platelet function assays that assess response to P2Y12 antagonists vary widely in their sensitivities to low levels of P2Y12 receptor blockade. EUROPEAN HEART JOURNAL, 29, 835-835.
Ajjan R, Storey RF & Grant PJ (2008) Aspirin resistance and diabetes mellitus. DIABETOLOGIA, 51(3), 385-390.
Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA & Storey RF (2008) The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.. Platelets, 19(2), 125-133.
Kleiman NS, Freedman JE, Tracy PB, Furie BC, Bray PF, Rao SV, Phillips DR, Storey RF, Rusconi CP, French PA , Steinhubl SR et al (2008) Platelets: Developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. PLATELETS, 19(4), 239-251.
Storey RF (2007) ARL66096, 1-2.
Storey RF (2007) AR-C69931MX, 1-4.
Storey RF (2007) ARL67085, 1-3.
Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G & Storey RF (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial (vol 50, pg 1844, 2007). J AM COLL CARDIOL, 50(22), 2196-2196.
Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Storey RF & DISPERSE-2 Invest (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial. J AM COLL CARDIOL, 50(19), 1844-1851.
Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P & Cannon CP (2007) Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.. J Am Coll Cardiol, 50(19), 1852-1856.
Judge HM & Storey RF (2007) Abciximab can potentiate platelet alpha-granule release and this effect is prevented by the P2Y12 antagonist cangrelor. EUROPEAN HEART JOURNAL, 28, 665-666.
Patil SBG, Norman KE, Robins SJ, Crosdale DJ, Nylander S, Francis SE & Storey RF (2007) INHIBITION OF THROMBOSIS BY AZD6140 VIA SELECTIVE BLOCKADE OF THE P2Y12 RECEPTOR IN A MURINE LASER-INJURY MODEL. Journal of Thrombosis and Haemostasis, 5.
Siotia A, Buckland R, Judge HM, Sastry P & Storey RF (2006) Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.. Thromb Haemost, 95(6), 997-1002.
Smith SMG, Judge HM, Peters G, Armstrong M, Fontana P, Gaussem P, Daly ME & Storey RF (2006) Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.. Platelets, 17(4), 250-258.
Storey RF (2006) Biology and pharmacology of the platelet P2Y12 receptor.. Curr Pharm Des, 12(10), 1255-1259.
Judge HM, Buckland RJ, Holgate CE & Storey RF (2005) Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.. Platelets, 16(7), 398-407.
Ward JR, Bingle L, Judge HM, Brown SB, Storey RF, Whyte MKB, Dower SK, Buttle DJ & Sabroe I (2005) Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor.. Thromb Haemost, 94(4), 831-838.
Smith SMG, Judge HM, Peters G, Armstrong M, Dupont A, Gaussem P & Storey RF (2005) PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.. Platelets, 16(6), 340-345.
Akowuah E, Shrivastava V, Jamnadas B, Hopkinson D, Sarkar P, Storey R, Braidley P & Cooper G (2005) Comparison of Two Strategies for the Management of Antiplatelet Therapy During Urgent Surgery. The Annals of Thoracic Surgery, 80(1), 149-152.
Behan MWH, Fox SC, Heptinstall S & Storey RF (2005) Inhibitory effects of P2Y(12) receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. PLATELETS, 16(2), 73-80.
Storey RF, May JA & Heptinstall S (2005) Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.. Thromb Res, 115(4), 301-307.
Smith SMG, Judge HM, Peters G & Storey RF (2004) Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.. Platelets, 15(8), 465-474.
Heptinstall S, Glenn JR, May JA, Storey RF & Wilcox RG (2004) Clopidogrel resistance.. Catheter Cardiovasc Interv, 63(3), 397-398.
Storey RF (2004) Anticoagulants, antiplatelets and thrombolytics. British Journal of Clinical Pharmacology, 58(4), 442-442.
Behan MWH & Storey RF (2004) Antiplatelet therapy in cardiovascular disease. POSTGRAD MED J, 80(941), 155-164.
Storey RF, Wilcox RG & Heptinstall S (2002) Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.. Platelets, 13(7), 407-413.
Storey RF, Judge HM, Wilcox RG & Heptinstall S (2002) Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.. Thromb Haemost, 88(3), 488-494.
Storey RF, Newby LJ & Heptinstall S (2001) Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood.. Platelets, 12(7), 443-447.
Storey RF (2001) The P2Y12 receptor as a therapeutic target in cardiovascular disease.. Platelets, 12(4), 197-209.
Storey RF, Oldroyd KG & Wilcox RG (2001) Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.. Thromb Haemost, 85(3), 401-407.
Storey RF, Sanderson HM, White AE, May JA, Cameron KE & Heptinstall S (2000) The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.. Br J Haematol, 110(4), 925-934.
Storey RF, Sanderson HM & Heptinstall S (2000) P2T receptor activation by released ADP dramatically amplifies platelet procoagulant activity and calcium mobilisation induced by thrombin receptor (PAR1) activation. EUR HEART J, 21, 66-66.
Storey RF, Curry SN & Heptinstall S (2000) In vitro evidence supporting direct platelet P2T receptor antagonism as an alternative strategy to glycoprotein IIB/IIIA receptor antagonism. Heart, 83(SUPPL. 1).
Storey RF, May JA & Heptinstall S (1999) O4 Heparins sensitize platelets to responses mediated via both the P27 and the P2Y1 receptor pathways. Blood Coagulation & Fibrinolysis, 10(8), 531-531.
Storey RF, May JA & Heptinstall S (1999) Heparins sensitize platelets to responses mediated via both the P-2T and the P2Y(1) receptor pathways. CIRCULATION, 100(18), 680-680.
Storey RF, Oldroyd KG & Wilcox RG (1999) First clinical study of the novel platelet ADP receptor (P-2 gamma) antagonist AR-C69931MX, assessing safety, tolerability and activity in patients with acute coronary syndromes. CIRCULATION, 100(18), 710-710.
Storey RF, May JA, Wilcox RG & Heptinstall S (1999) A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.. Thromb Haemost, 82(4), 1307-1311.
Storey RF & Heptinstall S (1999) Laboratory investigation of platelet function.. Clin Lab Haematol, 21(5), 317-329.
Glusa E, Storey RF, Sanderson HM & Heptinstall S (1999) Influence of the ADP antagonists AR-C67085 and A2P5P on ADP-induced responses of platelets and isolated arteries. BRIT J PHARMACOL, 128, U31-U31.
Heptinstall S, Sanderson HM, Glenn JR, Storey RF & Losche W (1999) Does occupation of the P-2t, receptor on platelets by ADP lead to a reduced rate of Ca2+ re-uptake following Ca2+liberation via the P2Y(1) receptor, and is this mediated by a fall in basal camp?. THROMB HAEMOSTASIS, 355-356.
Storey RF, Cameron KE, Newby LJ, May JA, Wilcox RG & Heptinstall S (1999) Contribution of P-2t, and P2Y(1), receptors to ADP-induced platelet microaggregation in human whole blood. THROMB HAEMOSTASIS, 260-260.
Sanderson HM, Storey RF, Wilcox RG & Heptinstall S (1999) The effects of a P-2T antagonist on platelet aggregation, platelet activation and platelet-leukocyte conjugate formation in vitro and following administration to patients with unstable angina. THROMB HAEMOSTASIS, 11-11.
Glusa E, Storey RF, Sanderson HM & Heptinstall S (1999) Influence of the ADP antagonists AR-C67085 and A2P5P on ADP-induced responses of platelets and isolated arteries. THROMB HAEMOSTASIS, 166-167.
Sanderson HM, Storey RF & Heptinstall S (1999) Administration of a GPIIb/IIIa antagonist to patients with unstable angina: Effects on platelet aggregation and platelet-leucocyte conjugate formation. THROMB HAEMOSTASIS, 357-358.
Storey RF, White A, May JA, Newby LJ & Heptinstall S (1999) The central role of the P-2T receptor in amplification of platelet aggregation and secretion. THROMB HAEMOSTASIS, 420-420.
Storey RF, May JA, Wilcox RG & Heptinstall S (1999) Monitoring the effects of glycoprotein IIb/IIIa antagonists using a whole blood assay of platelet microaggregation: Comparison with other aggregation methodologies. Hamostaseologie, 19(3), 115-118.
Storey RF, Glenn J & Heptinstall S (1998) In vitro effects of the novel platelet adenosine diphosphate receptor (P-2T) antagonist AR-C69931MX and aspirin on platelet aggregation in human whole blood: a potential new therapy for arterial thrombosis.. CIRCULATION, 98(17), 560-560.
Storey RF, Wilcox RG & Heptinstall S (1998) Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.. Circulation, 98(16), 1616-1621.
Storey R (1998) Electrocardiogram interpretation - Response. JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON, 32(1), 85-85.
Storey RF & Rowley JM (1997) Electrocardiogram interpretation as a basis for thrombolysis.. J R Coll Physicians Lond, 31(5), 536-540.
Parker WAE & Storey RF () Oral anticoagulation and non-steroidal anti-inflammatory drugs: a recipe for bleeding. European Heart Journal.
Kunadian V, Mossop H, Shields C, Bardgett M, Watts P, Teare MD, Pritchard J, Adams-Hall J, Runnett C, Ripley DP , Carter J et al () Invasive Treatment Strategy for Older Patients with Myocardial Infarction. New England Journal of Medicine.
Sammut MA, Conway D, Iqbal J, Krishnamurthy A, Morgan KP, Morris PD, Richardson JD, Rothman AMK, Gunn JP & Storey RF () Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation. Expert Review of Cardiovascular Therapy, 1-7.
Wang K-L, Taggart C, McDermott M, O'Brien R, Oatey K, Keating L, Storey RF, Felmeden D, Curzen N, Kardos A , Roobottom C et al () Clinical decision aids and computed tomography coronary angiography in patients with suspected acute coronary syndrome. Emergency Medicine Journal.
Ghobrial M, Haley H, Gosling R, Taylor DJ, Richardson J, Morgan K, Barmby D, Iqbal J, Krishnamurthy A, Singh R , Conway D et al () Modelled impact of virtual fractional flow reserve in patients undergoing coronary angiography (VIRTU-4). Heart.
Storey RF () Individualising Antithrombotic Strategies for Acute and Chronic Coronary Syndromes. Interventional Cardiology: Reviews, Research, Resources, 19.
Schmoeckel M, Thielmann M, Hassan K, Geidel S, Schmitto J, Meyer AL, Vitanova K, Liebold A, Marczin N, Bernardi MH , Tandler R et al () Intraoperative haemoadsorption for antithrombotic drug removal during cardiac surgery: initial report of the international safe and timely antithrombotic removal (STAR) registry. Journal of Thrombosis and Thrombolysis.
Eggers KM, Batra G, Lindahl B, Ghukasyan Lakic T, Lindbäck J, Budaj A, Cornel JH, Giannitsis E, Katus HA, Storey RF , Becker RC et al () Temporal biomarker concentration patterns during the early course of acute coronary syndrome. Clinical Chemistry and Laboratory Medicine (CCLM), 0(0).
Al Said S, Kaier K, Sumaya W, Alsaid D, Duerschmied D, Storey RF, Gibson CM, Westermann D & Alabed S () Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. Cochrane Database of Systematic Reviews, 2024(1).
Landi A, Aboyans V, Angiolillo DJ, Atar D, Capodanno D, Fox KAA, Halvorsen S, James S, Jüni P, Leonardi S , Mehran R et al () Antithrombotic Therapy in Patients with Acute Coronary Syndrome: Similarities and Differences between a European Expert Consensus Document and the 2023 European Society of Cardiology Guidelines. European Heart Journal: Acute Cardiovascular Care.
James S, Storey RF & Oldgren J () Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure. European Heart Journal - Cardiovascular Pharmacotherapy.
James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, Andersen K, Austin D, Arefalk G, Carrick D , Hofmann R et al () Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evidence.
Gehin M, Storey RF, Bernaud C & Dingemanse J () Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction. Expert Opinion on Drug Metabolism & Toxicology, 1-12.
Parker WAE & Storey RF () THE ROLE OF PLATELET P2Y₁₂ IN INFLAMMATION. British Journal of Pharmacology.
Bonaca M, Lesén E, Giannitsis E, Hedberg J, Jernberg T, Lambrelli D, Duong M, Maggioni AP, Ariza-Solé A, ten Berg J & Storey RF () Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study. European Heart Journal - Cardiovascular Pharmacotherapy.
van den Broek WWA, Gimbel ME, Chan Pin Yin DRPP, Azzahhafi J, Hermanides RS, Runnett C, Storey RF, Austin D, Oemrawsingh R, Cooke J , Galasko G et al () Conservative versus Invasive Strategy in Elderly Patients with Non-ST-Elevation Myocardial Infarction: Insights from the International POPular Age Registry. Journal of Clinical Medicine, 12(17), 5450-5450.
Gorog DA, Ferreiro JL, Ahrens I, Ako J, Geisler T, Halvorsen S, Huber K, Jeong Y-H, Navarese EP, Rubboli A , Sibbing D et al () De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis. Nature Reviews Cardiology.
Gigante B, Levy JH, van Gorp E, Bartoloni A, Bochaton-Piallat M-L, Bäck M, ten Cate H, Christersson C, Ferreiro JL, Geisler T , Lutgens E et al () Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis. European Heart Journal.
Cao D, Amabile N, Chiarito M, Lee VT, Angiolillo DJ, Capodanno D, Bhatt DL, Mack MJ, Storey RF, Schmoeckel M , Gibson CM et al () Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding. European Heart Journal.
Navarese EP, Landi A, Oliva A, Piccolo R, Aboyans V, Angiolillo D, Atar D, Capodanno D, Fox KAA, Halvorsen S , James S et al () Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease. Two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC) and European Association of Preventive Cardiology (EAPC). European Heart Journal - Cardiovascular Pharmacotherapy.
Hjort M, Eggers KM, Lakic TG, Lindbäck J, Budaj A, Cornel JH, Giannitsis E, Katus HA, Siegbahn A, Storey RF , Becker RC et al () Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial. Journal of the American Heart Association.
Ajjan RA, Heller SR, Everett CC, Vargas-Palacios A, Higham R, Sharples L, Gorog DA, Rogers A, Reynolds C, Fernandez C , Rodrigues P et al () Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial. Diabetes Care.
Andreotti F, Geisler T, Collet J-P, Gigante B, Gorog DA, Halvorsen S, Lip GYH, Morais J, Navarese EP, Patrono C , Rocca B et al () Acute, periprocedural and longterm antithrombotic therapy in older adults. European Heart Journal.
Bonaca MP, Im K, Magnani G, Bansilal S, Dellborg M, Storey RF, Bhatt DL, Steg PG, Cohen M, Johanson P , Braunwald E et al () Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. European Heart Journal.
Mehta SR, Wang J, Wood DA, Spertus JA, Cohen DJ, Mehran R, Storey RF, Steg PG, Pinilla-Echeverri N, Sheth T , Bainey KR et al () Complete Revascularization vs Culprit Lesion–Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction. JAMA Cardiology.
Rikken SAOF, Storey RF, Andreotti F, Clemmensen P & ten Berg JM () Parenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future Directions. Thrombosis and Haemostasis.
Geisler T, Poli S, Huber K, Rath D, Aidery P, Kristensen SD, Storey RF, Ball A, Collet J-P & Berg JT () Resumption of Antiplatelet Therapy after Major Bleeding. Thrombosis and Haemostasis.
Batra G, Renlund H, Kunadian V, James SK, Storey RF, Steg PG, Katus HA, Harrington RA, Gibson CM, Budaj A , Siegbahn A et al () Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. European Heart Journal. Acute Cardiovascular Care.
() Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. BMJ, o438-o438.
Parker WAE & Storey RF () Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?. Cardiovascular Research.
Lesén E, Hewitt C, Giannitsis E, Hedberg J, Jernberg T, Lambrelli D, Maggioni AP, Simeone JC, Ariza‐Solé A, Storey RF , Berg J et al () Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA , a multi‐country observational study. Clinical Cardiology.
Dehghani P, Cantor WJ, Wang J, Wood DA, Storey RF, Mehran R, Bainey KR, Welsh RC, Rodés-Cabau J, Rao S , Lavi S et al () Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial. Circulation: Cardiovascular Interventions.
Ajjan RA, Kietsiriroje N, Badimon L, Vilahur G, Gorog DA, Angiolillo DJ, Russell DA, Rocca B & Storey RF () Antithrombotic therapy in diabetes: which, when, and for how long?. European Heart Journal.
Hijazi Z, Alexander JH, Li Z, Wojdyla DM, Mehran R, Granger CB, Parkhomenko A, Bahit MC, Windecker S, Aronson R , Berwanger O et al () Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients with Atrial Fibrillation After Acute Coronary Syndrome or PCI: Insights from The AUGUSTUS Trial. Circulation.
Marston NA, Melloni GEM, Gurmu Y, Bonaca MP, Kamanu FK, Roselli C, Lee C, Cavallari I, Giugliano RP, Scirica BM , Bhatt DL et al () Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease. Circulation: Genomic and Precision Medicine.
Hennigan BW, Good R, Adamson C, Parker WAE, Martin L, Anderson L, Campbell M, Serruys PW, Storey RF & Oldroyd KG () Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. Platelets, 1-6.
Jones R, Varian F, Alabed S, Morris P, Rothman A, Swift AJ, Lewis N, Kyriacou A, Wild JM, Al‐Mohammad A , Zhong L et al () Meta‐analysis of echocardiographic quantification of left ventricular filling pressure. ESC Heart Failure.
Marston NA, Patel PN, Kamanu FK, Nordio F, Melloni GM, Roselli C, Gurmu Y, Weng L-C, Bonaca MP, Giugliano RP , Scirica BM et al () Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease. Circulation.
Krychtiuk KA, Speidl WS, Giannitsis E, Gigante B, Gorog DA, Jaffe AS, Mair J, Möckel M, Mueller C, Storey RF , Vilahur G et al () Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. European Heart Journal. Acute Cardiovascular Care.
Parker WAE & Storey RF () Antithrombotic therapy for patients with chronic coronary syndromes. Heart.
Ono M, Tomaniak M, Koenig W, Khamis R, de Silva R, Chichareon P, Kawashima H, Hara H, Gao C, Wang R , Huber K et al () Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial. European Heart Journal - Cardiovascular Pharmacotherapy.
Marston NA, Bonaca MP, Jarolim P, Goodrich EL, Bhatt DL, Steg PG, Cohen M, Storey RF, Johanson P, Wiviott SD , Braunwald E et al () Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiology.
Morales-Rosado JA, Goel K, Zhang L, Åkerblom A, Baheti S, Black JL, Eriksson N, Wallentin L, James S, Storey RF , Goodman SG et al () Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. Cardiovascular Drugs and Therapy.
Bainey KR, Engstrøm T, Smits PC, Gershlick AH, James SK, Storey RF, Wood DA, Mehran R, Cairns JA & Mehta SR () Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction. JAMA Cardiology.
King RJ, Schuett K, Tiede C, Jankowski V, John V, Trehan A, Simmons K, Ponnambalam S, Storey RF, Fishwick CWG , McPherson MJ et al () Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. Haematologica, haematol.2019.239558-haematol.2019.239558.
Gorog DA, Price S, Sibbing D, Baumbach A, Capodanno D, Gigante B, Halvorsen S, Huber K, Lettino M, Leonardi S , Morais J et al () Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal - Cardiovascular Pharmacotherapy.
Parker WAE & Storey RF () Novel approaches to P2Y12 inhibition and aspirin dosing. Platelets, 1-8.
Ow KW, Parker WAE, Porter MM, Hanson J, Judge HM, Briffa NP, Thomas MR & Storey RF () Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Platelets, 1-7.
Kontny F, Andersen T, Ueland T, Åkerblom A, Lakic TG, Michelsen AE, Aukrust P, Bertilsson M, Becker RC, Himmelmann A , James SK et al () Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial. European Heart Journal: Acute Cardiovascular Care, 204887261984633-204887261984633.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Mickley H, Crea F, Van de Werf F , Bucciarelli-Ducci C et al () Fourth universal definition of myocardial infarction (2018). Kardiologia Polska, 76(10), 1383-1415.
Parker WAE & Storey RF () Choosing a perspective on mortality with DAPT. European Heart Journal, ehv610-ehv610.
Magnani G, Storey RF, Steg G, Bhatt DL, Cohen M, Kuder J, Im K, Aylward P, Ardissino D, Isaza D , Parkhomenko A et al () Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal, ehv482-ehv482.
Andreotti F, Rocca B, Husted S, Ajjan RA, ten Berg J, Cattaneo M, Collet J-P, De Caterina R, Fox KAA, Halvorsen S , Huber K et al () Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, ehv304-ehv304.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD & For the Universal Definition of MI WGJESC () Third Universal Definition of Myocardial Infarction. Global Heart, 7(4), 275-275.
Sumaya W, Parker WAE, Judge HM, Hall IR, Orme RC, Adam Z, Richardson JD, Rothman AMK, Morgan KP, Gunn JP & Storey RF () Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Platelets. View this article in WRRO
Zwart B, Parker WAE & Storey RF () New Antithrombotic Drugs in Acute Coronary Syndrome. Journal of Clinical Medicine, 9(7), 2059-2059.
Storey RF, Gurbel PA, ten Berg J, Bernaud C, Dangas GD, Frenoux J-M, Gorog DA, Hmissi A, Kunadian V, James SK , Tanguay J-F et al () Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. European Heart Journal.
Åkerblom A, James SK, Lakic TG, Becker RC, Cannon CP, Steg PG, Himmelmann A, Katus HA, Storey RF, Wallentin L , Weaver WD et al () Interleukin‐18 in patients with acute coronary syndromes. Clinical Cardiology. View this article in WRRO
Åkerblom A, Wojdyla D, Steg PG, Wallentin L, James SK, Budaj A, Katus HA, Himmelmann A, Huber K, Siegbahn A , Storey RF et al () Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes : insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Journal of Thrombosis and Thrombolysis, 48(4), 563-569. View this article in WRRO

Chapters

Parker WAE, De Caterina R, Moliterno DJ, Kristensen SD & Storey RF (2023) Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes In De Caterina R, Moliterno DJ & Kristensen SD (Ed.), The ESC Textbook of Thrombosis (pp. 179-C16P154). Oxford University PressOxford
Verheugt FWA & Storey RF (2021) The conundrum of simultaneous antiplatelet and anticoagulant therapy: how to solve it?, Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease (pp. 193-199). Elsevier
Parker W & Storey R (2018) Acute coronary syndromes: Thrombotic Response
Thomas MR & Storey RF (2017) Platelets in Acute Coronary Syndromes, Platelets in Thrombotic and Non-Thrombotic Disorders (pp. 1015-1028). Springer International Publishing
Jackman LE & Storey RF (2009) Prasugrel In Editors-in-Chief: S.J. Enna & David B. Bylund (Ed.), xPharm: The Comprehensive Pharmacology Reference (pp. 1-4). New York: Elsevier.
Jackman LE & Storey RF (2009) MRS 2395 In Editors-in-Chief: S.J. Enna & David B. Bylund (Ed.), xPharm: The Comprehensive Pharmacology Reference (pp. 1-2). New York: Elsevier.

Conference proceedings papers

Parker WAE, Sundh J, Oldgren J, Konstantinidis KV, Lindback J, Janson C, Andell P, Bjorkenheim A, Elamin N, McMellon H , Moyle B et al (2023) S89 Prevalence of microspirometry-defined chronic obstructive pulmonary disease in two European cohorts of patients with significant smoking history hospitalised for acute myocardial infarction. ‘Total eclipse of the heart’ – COPD and cardiovascular disease
Elamin N, Nelson TA, Richardson JD, Adam Z, Krishnamurthy A, Iqbal J, Morgan KP, Hall IR, Rothman A, Parker WAE , Storey RF et al (2023) 71 Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention. Acute coronary syndromes & Interventional Cardiology
Hassan K, Thielmann M, Liebold A, Geidel S, Marzin N, Wendt D, Deliargyris E, Schmoeckel M & Storey R (2023) First Report of the International Safe and Timely Antithrombotic Removal (STAR) Registry. SWISS MEDICAL WEEKLY, Vol. 153 (pp 109S-109S)
Tiong D, Pinilla N, Wood D, Mehran R, Storey R, Feldman L, Moreno R, Rao S, Cantor W, Welsh R , Cohen E et al (2023) Effects of Complete Revascularization in Relation to Left Ventricular Function in Patients With STEMI and Multivessel Disease: Data from the COMPLETE Randomized trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 82(17) (pp B250-B251)
James SK, Erlinge D, Storey RF, McGuire DK, de Belder M, Andersen K, Austin D, Arefalk G, Carrick D, Hofmann R , Hoole SP et al (2023) DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes. CIRCULATION, Vol. 148(25) (pp E283-E284)
McGrath BP, Pinilla N, Wood DA, Bainey KR, Sheth T, Schampaert E, Tanguay J-F, Dzavik V, Storey RF, Mehran R , Bossard M et al (2023) Left Anterior Descending Non-culprit Lesion Location And Clinical Outcomes In Patients With St-segment Elevation Myocardial Infarction And Multivessel Disease: Results From The Complete Trial. CIRCULATION, Vol. 148(25) (pp E298-E298)
Shaji N, Elamin N, Nelson T, Varian F, Storey R & Parker W (2022) 171 Prevalence of a nice-defined indication for inclisiran in a real-world trans-pandemic acute coronary syndrome cohort. Stable IHD/Prevention/Hypertension/Lipids
Bainey K, Cairns J, Rao S, Wood D, Storey R, Mehran R, Cantor W, Lavi S, Rodes-Cabau J, Dzavik V , Dehghani P et al (2022) Effects of Complete Revascularization According to Age in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel: Insights From the COMPLETE Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 80(12) (pp B15-B15)
Oqab Z, Kunadian V, Wood D, Rao S, Mehran R, Pinilla N, Storey R, Boone R, Sibbald M, Valettas N , Moreno R et al (2022) Complete Revascularization Versus Culprit Lesion-Only PCI in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: A Subgroup Analysis of the COMPLETE Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 80(12) (pp B15-B15)
Van den Broek WW, Gimbel ME, Hermanides RS, Runnet C, Storey RF, Austin D, Oemrawsingh RM, Cooke J, Galasko G, Walhout R , Schellings DAAM et al (2022) Treatment and prognosis of elderly patients with non-ST-elevation myocardial infarction. EUROPEAN HEART JOURNAL, Vol. 43 (pp 2541-2541)
Hjort M, Eggers KM, Becker RC, Budaj A, Cornel JH, Giannitsis E, James SK, Katus HA, Lakic TG, Lindback J , Siegbahn A et al (2021) Temporal changes of biomarkers in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries. EUROPEAN HEART JOURNAL, Vol. 42 (pp 1491-1491)
Ono M, Onuma Y, Kawashima H, Hara H, Gao C, Wang R, O'Leary N, Garg S, Juni P, Hamm C , Valgimigli M et al (2021) Impact of Proton Pump Inhibitors on Efficacy of Antiplatelet Strategies With Ticagrelor or Aspirin After Percutaneous Coronary Intervention. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 78(19) (pp B82-B83)
Batra G, Lindback J, Becker RC, Harrington RA, Held C, James SK, Kempf T, Lagerqvist B, Lopes RD, Tricoci P , Mahaffey KW et al (2021) The Biomarker-Based ABC-ACS (Age, Biomarkers, Clinical History) Score Can Predict Major Bleeding Better Than Other Contemporary Scores in Patients on Dual Antiplatelet Therapy After Coronary Revascularization: Results of a Large Derivation and Validation Study. CIRCULATION, Vol. 144
Guimaraes P, Lopes RD, Wojdyla D, Alexander JH, Goodman SG, Aronson R, Halvorsen S, Sinnaeve PR, Vinereanu D, Storey RF , Berwanger OB et al (2021) Antithrombotic Strategies According to Age in Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the Augustus Trial. CIRCULATION, Vol. 144
Lesen E, Hewitt C, Giannitsis E, Hedberg J, Jernberg T, Lambrelli D, Lindholm D, Maggioni AP, Medin J, Schultze A , Sole AA et al (2020) Rationale, design and feasibility of conducting a real-world study of outcomes in patients with a history of MI receiving extended DAPT with ticagrelor 60 mg. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 29 (pp 129-129)
Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, Rachel O, Storey RF, Robert LJ, Lewis SE, Thokala P & David NE (2020) Rapid Assessment of Potential Ischaemic Heart Disease With Ctca: The Rapid-ctca Trial. A Randomised Trial of Ctcain the Evaluation, Intervention and Outcome Ofadults With Suspected or Confirmed Acute Coronary Syndrome Presenting to the Emergency Department. CIRCULATION, Vol. 142(24) (pp E471-E472)
Patel PN, Marston NA, Kamanu FK, Weng LC, Bonaca MP, Giugliano RP, Scirica BM, O'Donoghue ML, Cannon CP, Anderson CD , Bhatt DL et al (2020) A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. CIRCULATION, Vol. 142
Tomaniak M, Chichareon P, Takahashi K, Kogame N, Modolo R, Chang CC, Katagiri Y, Cano ES, Neumann F-J, Plante S , Antolin RH et al (2019) LONG-TERM SAFETY OF TICAGRELOR MONOTHERAPY IN PATIENTS UNDERGOING PCI FOR STABLE CORONARY ARTERY DISEASE IN THE GLOBAL LEADERS STUDY: IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Journal of the American College of Cardiology, Vol. 73(9) (pp 196-196)
Echeverri NP, Mehta SR, Wang J, Lavi S, Wood DA, Cantor W, Bainey KR, Kassam S, Schampaert E, Mehran R , Storey RF et al (2019) Non-Culprit Lesion Plaque Morphology in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography (OCT) Substudy. CIRCULATION, Vol. 140(25) (pp E982-E983)
Sumaya W, Parker W, Judge HM, Hall IR, Orme RC, Adam Z, Richardson JD, Rothman AM, Morgan KP, Gunn JP & Storey RF (2019) Prolonged Enoxaparin Infusion in Patients Undergoing Primary Percutaneous Coronary Intervention Compared to Standard-of-care: A Single-centre Clinical Trial. CIRCULATION, Vol. 140
Zhang L, Morales-Rosado JA, Goel K, Akerblom A, Baheti S, Black J, Eriksson N, Wallentin LC, James SK, Storey RF , Goodman SG et al (2019) Novel CYP2C19 Genetic Variants Associated With Stent Thrombosis - A Next Generation Sequencing Study. CIRCULATION, Vol. 140
Tomaniak M, Chichareon P, Modolo R, Plante S, Brunel P, Beygui F, Van Geuns R-J, Storey R, Hamm C, Steg PG , Vranckx P et al (2019) Dyspnea in ticagrelor treated patients in the all-comer randomized GLOBAL LEADERS study and its association with clinical outcomes. EUROPEAN HEART JOURNAL, Vol. 40 (pp 4011-4011)
Iqbal A, Prince L, Novodvorsky P, Bernjak A, Thomas M, Birch L, Lambert D, Kay L, Wright F, Jacques R , Storey R et al (2018) Acute hypoglycaemia results in increased activation of responses to an inflammatory challenge induced 48 hours later in human subjects. DIABETOLOGIA, Vol. 61 (pp S446-S446)
Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Himmelmann A, Ajjan RA & Storey RF (2018) Impaired fibrin clot lysis persists at 1 month post ACS: a PLATO substudy. EUROPEAN HEART JOURNAL, Vol. 39 (pp 882-883)
Lindholm D, James S, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A , Wallentin L et al (2018) Multiple biomarkers and cause-specific mortality in patients with acute coronary syndromes - Insights from the PLATO biomarker substudy. EUROPEAN HEART JOURNAL, Vol. 39 (pp 145-146)
Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, Himmelmann A, Ajjan R & Storey RF (2018) Adverse Fibrin Clot Properties Are Associated With Worse Outcome Following Acute Coronary Syndrome: A PLATO Substudy. CIRCULATION, Vol. 136 View this article in WRRO
Geisler T, Muenzer P, Alnaggar N, Geue S, Tegtmeyer R, Rath D, Droppa M, Seizer P, Heitmeier S, Heemskerk JWM , Jennings L et al (2018) INHIBITORY MECHANISMS OF VERY LOW DOSE RIVAROXABAN IN NON-ST-ELEVATION MYOCARDIAL INFARCTION. Journal of the American College of Cardiology, Vol. 71(11) (pp A1398-A1398)
Parker W, Orme RC, Sumaya W, Hanson J, Stokes H, McMellon H, Shaw P, Judge H & Storey R (2018) ULTRA-LOW-DOSE TWICE-DAILY ASPIRIN IMPROVES HEMOSTASIS AND MAINTAINS PLATELET INHIBITION IN ACUTE CORONARY SYNDROME PATIENTS RECEIVING TICAGRELOR. Journal of the American College of Cardiology, Vol. 71(11) (pp A30-A30)
Bonaca MP, Giugliano RP, Nault P, Scirica BM, Pedersen TR, Bhatt DL, Keech AC, Storey RF, Steg PG, Cohen M , Goodrich EM et al (2018) Patient Selection for Therapies to Prevent Major Adverse Limb Events. CIRCULATION, Vol. 138
Furtado RH, Bhatt DL, Steg PG, Cohen M, Storey RF, Im KW, Sabatine MS & Bonaca MP (2018) Long-Term Secondary Prevention With Ticagrelor for Prior Myocardial Infarction in Patients With No Coronary Stenting: A Sub-Analysis From PEGASUS TIMI 54. CIRCULATION, Vol. 138
Marston NA, Bonaca MP, Jarolim P, Bhatt DL, Steg PG, Cohen M, Storey RF, Johanson P, Goodrich E, Wiviott SD , Braunwald E et al (2018) High-Sensitivity Cardiac Troponin at Any Detectable Concentration Identifies Higher Risk of Major Cardiovascular Events in Patients With Stable Ischemic Heart Disease. CIRCULATION, Vol. 138
Furtado RH, Venkateswaran R, Bhatt DL, Storey RF, Steg PG, Cohen M, Gurmu Y, Johanson P, Sabatine MS & Bonaca MP (2018) Caffeine and Dyspnea With Ticagrelor: A Sub-Analysis From PEGASUS TIMI-54 Trial. CIRCULATION, Vol. 138
Iqbal A, Thomas M, Novodvorsky P, Bernjak A, Birch L, Lambert D, Kay L, Wright F, Prince L, Francis S , Storey R et al (2017) Hypoglycaemia increases platelet reactivity and promotes formation of proatherogenic platelet-leucocyte aggregates. DIABETOLOGIA, Vol. 60 (pp S532-S532)
Bonaca M, Jarolim P, Goodrich EL, Storey RF, Bhatt DL, Steg PG, Cohen M, Jensen E, Johanson R, Braunwald E , Morrow DA et al (2017) Growth differentiation factor 15 and bleeding risk with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. EUROPEAN HEART JOURNAL, Vol. 38 (pp 612-612)
Iqbal A, Thomas M, Novodvorsky P, Bernjak A, Birch L, Lambert D, Kay L, Wright F, Prince L, Francis S , Storey R et al (2017) Effect of Hypoglycemia on Platelet Reactivity and Platelet-Leukocyte Kinetics. DIABETES, Vol. 66 (pp A41-A41)
Weng Ow K, Thomas M, Parker W, Judge H & Storey R (2017) 72 Offset of ticagrelor prior to coronary artery bypass graft surgery (cabg) surgery. Heart, Vol. 103(Suppl 5) (pp A53.2-A54)
Gosling R, Yazdani M, Parviz Y, Hall I, Grech E, Gunn J, Storey R & Iqbal J (2017) COMPARISON OF P2Y12 INHIBITORS FOR MORTALITY AND STENT THROMBOSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES: SINGLE CENTRE STUDY OF 10,793 CONSECUTIVE ‘REAL-WORLD’ PATIENTS. Journal of the American College of Cardiology, Vol. 69(11) (pp 1014-1014)
Ueland T, Akerblom A, Ghukasyan T, Michelsen AE, Aukrust P, Becker RC, Bertilsson M, Himmelmann A, James SK, Siegbahn A , Storey RF et al (2016) Osteoprotegerin is Associated With Major Bleeding but Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes - Insights From the PLATelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, Vol. 134
Ueland T, Akerblom A, Ghukasyan T, Michelsen AE, Aukrust P, Becker RC, Bertilsson M, Himmelmann A, James SK, Siegbahn A , Storey RF et al (2016) Osteoprotegerin is Associated With Major Bleeding but Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes - Insights From the PLATelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, Vol. 134
Van't Hof A, Fabris E, Giannini F, Johanne S, Rousseau E, Vicaut E, Cequier A, Tsatsaris A, Huber K, Hamm C , Janzon M et al (2016) Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: the ATLANTIC ST-segment resolution substudy. EUROPEAN HEART JOURNAL, Vol. 37 (pp 1173-1173)
Varenhorst CV, Akerblom A, Renlund H, Kunadian V, James SK, Steg PG, Katus HA, Himmelmann A, Aylward P, Maurer G , Storey RF et al (2016) Successful reperfusion is associated with lower levels of markers of myocardial damage and dysfunction in ST-elevation but not in non-ST-elevation myocardial infarction: insights from the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 37 (pp 1282-1283)
Franchi F, Angiolillo DJ, Ghukasyan T, Budaj A, Cornel JH, Husted S, Katus HA, Keltai M, Kontny F, Lewis BS , Storey RF et al (2016) Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 37 (pp 1224-1224)
Thomas MR, Iqbal A, Outteridge SN, Judge HM, Dockrell DH, Sabroe I & Storey RF (2016) Platelet P2Y12 inhibitors enhance expansion of the intermediate monocyte population following systemic inflammation in humans. EUROPEAN HEART JOURNAL, Vol. 37 (pp 904-904)
Cavallari I, Aylward P, Steg PG, Storey RF, Bhatt DL, Cohen M, Budaj A, Corbalan R, Theroux P, Lopez-Sendon J , Isaza D et al (2016) Potential role of ticagrelor in preventing venous and cardiac thrombosis: insights from PEGASUS-TIMI 54. EUROPEAN HEART JOURNAL, Vol. 37 (pp 636-637)
Horne A, Gunn J, Iqbal J, Morgan K, Hall I, West J, Grech E, Barmby D, Wheeldon N, Storey R & Richardson J (2016) 27 Impact of Culprit Versus Non-Culprit Angiography Strategy on Primary PCI Door to Balloon Times. Heart, Vol. 102(Suppl 6) (pp A18-A18)
Åkerblom A, James S, Bertilsson M, Himmelmann A, Huhn M, Pieper K, Husted S, Storey R, Becker R & Wallentin L (2016) SERUM URIC ACID IS ASSOCIATED WITH CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROMES: RESULTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 67(13) (pp 556-556)
Lindholm D, Lindbäck J, James S, Becker R, Cornel J, Himmelmann A, Giannitsis E, Harrington R, Held C, Husted S , Katus H et al (2016) PREDICTION OF MAJOR BLEEDING IN REVASCULARIZED PATIENTS WITH ACUTE CORONARY SYNDROMES: DEVELOPMENT OF A NOVEL BIOMARKER-BASED CLINICAL PREDICTION MODEL. Journal of the American College of Cardiology, Vol. 67(13) (pp 493-493)
Bonaca MP, Bhatt D, Storey R, Steg P, Cohen M, Kuder J, Im K, Held P, Jensen E, Braunwald E & Sabatine M (2016) EFFICACY AND SAFETY OF TICAGRELOR AS LONG-TERM SECONDARY PREVENTION IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION AND PERIPHERAL ARTERY DISEASE. Journal of the American College of Cardiology, Vol. 67(13) (pp 2266-2266)
Bansilal S, Bonaca M, Cornel JH, Storey R, Bhatt D, Steg P, Im K, Held P, Jensen E, Braunwald E , Sabatine M et al (2016) EFFICACY AND SAFETY OF TICAGRELOR FOR LONG-TERM SECONDARY PREVENTION OF ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH PRIOR MI AND MULTIVESSEL CORONARY DISEASE: INSIGHTS FROM THE PEGASUS-TIMI 54 TRIAL. Journal of the American College of Cardiology, Vol. 67(13) (pp 2146-2146)
Bhatt DL, Bonaca M, Bansilal S, Cohen M, Storey RF, Im K, Murphy S, Held P, Braunwald E, Sabatine M & Steg PG (2016) REDUCTION IN ISCHEMIC EVENTS WITH TICAGRELOR IN DIABETIC PATIENTS FROM THE PEGASUS-TIMI 54 TRIAL. Journal of the American College of Cardiology, Vol. 67(13) (pp 2111-2111)
Bonaca MP, Bhatt DL, Ophuis TO, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A , Theroux P et al (2015) Long-Term Tolerability of Ticagrelor in the PEGASUS-TIMI 54 Trial. CIRCULATION, Vol. 132(23) (pp 2272-2272)
Murphy SA, Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Deenadayalu N, Kuder JF, Magnani G, Theroux P , Nicolau JC et al (2015) Reduction in Total Cardiovascular Events With Long-term Use of Ticagrelor in Patients With Prior Myocardial Infarction in the PEGASUS-TIMI 54 Trial. CIRCULATION, Vol. 132
Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Im K, Magnani G, Ophuis TO, Ruda M, Parkhomenko A , Isaza D et al (2015) Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54. CIRCULATION, Vol. 132
Lindholm D, Hagstrom E, James SK, Becker RC, Cannon CP, Himmelmann A, Husted S, Katus HA, Maurer G, Lopez-Sendon J , Steg PG et al (2015) GDF-15 at One Month After an Acute Coronary Syndrome is Associated With Increased Risk of Major Bleeding - A PLATO Biomarker Substudy. CIRCULATION, Vol. 132
Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Kuder J, Murphy SA, Magnani G , Budaj A et al (2015) Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. CIRCULATION, Vol. 132
Bonaca MP, Bhatt DL, Steg PG, Budaj A, Bansilal S, Storey RF, Im K, Magnani G, Ophuis TO, Ruda M , Hamm C et al (2015) TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54. Journal of the American College of Cardiology, Vol. 66(15) (pp B36-B36)
Magnani G, Sabatine MS, Bhatt DL, Choen M, Steg G, Storey R, Kuder J, Murphy S, Braunwald E & Bonaca MP (2015) Efficacy and Safety of Ticagrelor for Long-Term Secondary Prevention of Atherothrombotic Events in Relation to Renal Function: Insights from the PEGASUS-TIMI 54 trial. EUROPEAN HEART JOURNAL, Vol. 36 (pp 520-520)
Cayla G, Lapostolle F, Hammett CJ, Merkely B, Lassen JF, Storey RF, Ten Berg JM, Hamm CW, Van 'T Hof AW & Montalescot G (2015) Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: the French subgroup analysis of the ATLANTIC study. EUROPEAN HEART JOURNAL, Vol. 36 (pp 68-68)
Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, Husted S, Storey RF, Wallentin L, Steg PG & Investigators PLATOT (2015) Balancing the risk of ischaemic and bleeding events in ACS. EUROPEAN HEART JOURNAL, Vol. 36 (pp 860-861)
O'Donoghue ML, Bonaca MP, Magnani G, Bhatt DL, Cohen M, Steg PG, Storey RF, Murphy SM, Braunwald E & Sabatine MS (2015) The efficacy and safety of ticagrelor in women versus men with a prior myocardial infarction: insights from the PEGASUS-TIMI 54 trial. EUROPEAN HEART JOURNAL, Vol. 36 (pp 549-549)
Kaudewitz D, Skroblin P, Willeit K, Willeit P, Barwari T, Zampetaki A, Morton AC, Kiechl S, Storey RF & Mayr M (2015) Associations of plasma microRNAs with platelet proteins and platelet function. EUROPEAN HEART JOURNAL, Vol. 36 (pp 230-230)
Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Bhatt DL, Steg PG, Ahsan AJ, Kuder J, Braunwald E & Sabatine MS (2015) Ticagrelor 60 mg twice-daily provides effective platelet inhibition in patients with prior myocardial infarction: the PEGASUS-TIMI 54 platelet function substudy. EUROPEAN HEART JOURNAL, Vol. 36 (pp 549-549)
Thomas M, Ajjan R, Phoenix F, Outteridge S, Dockrell D, Sabroe I & Storey R (2015) 203 Ticagrelor and Clopidogrel Attenuate the Prothrombotic State induced by Bacterial Endotoxaemia. Heart, Vol. 101(Suppl 4) (pp A112.1-A112)
Silvain J, Storey R, Cayla G, Esteve J-B, Dillinger J-G, Vicaut E, Collet J-P, Tsatsaris A, Licour M, Salhi N , Lapostolle F et al (2015) IMPACT OF MORPHINE ADMINISTRATION ON TICAGRELOR-INDUCED PLATELET INHIBITION IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED BY PRIMARY PCI: RESULTS FROM THE PRIVATE-ATLANTIC STUDY. Journal of the American College of Cardiology, Vol. 65(10) (pp A15-A15)
Wallentin L, Michelsen AE, Aukrust P, Becker R, Bertilsson M, Budaj A, Cornel J, Himmelmann A, Husted S, Siegbahn A , Storey R et al (2015) ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE (ALCAM) AND OUTCOMES IN ACUTE CORONARY SYNDROMES: A PLATO BIOMARKER SUBSTUDY. Journal of the American College of Cardiology, Vol. 65(10) (pp A231-A231)
Silvain J, Storey R, Cayla G, Esteve J-B, Dillinger J-G, Vicat E, Collet J-P, Tsatsaris A, Baradat C, Salhi N , Lapostolle F et al (2015) P2Y12 RECEPTOR INHIBITION ACCORDING TO PREHOSPITAL ADMINISTRATION OF TICAGRELOR IN PRIMARY PCI FOR ST ELEVATION MYOCARDIAL INFARCTION: THE PRIVATE-ATLANTIC STUDY. Journal of the American College of Cardiology, Vol. 65(10) (pp A221-A221)
Andell P, James S, Cannon C, Cyr D, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg P , Storey R et al (2015) TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN ANALYSIS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 65(10) (pp A114-A114)
Thomas MR, Ajjan RA, Phoenix F, Outteridge SN, Dockrell DH, Sabroe I & Storey RF (2015) TICAGRELOR INHIBITS CHANGES IN FIBRIN CLOT STRUCTURE INDUCED BY BACTERIAL ENDOTOXEMIA. Journal of the American College of Cardiology, Vol. 65(10) (pp A12-A12)
Thomas MR, Alsharif KF, Prince LR, Ridger VC, Judge HM, Dockrell DH, Sabroe I & Storey RF (2015) TICAGRELOR POTENTIATES NEUTROPHIL PHAGOCYTOSIS VIA INHIBITION OF ADENOSINE REUPTAKE BY ERYTHROCYTES. Journal of the American College of Cardiology, Vol. 65(10) (pp A259-A259)
Bender L, Mayr M, Kaudewitz D, Skroblin P, Willeit P, Morton A, Gracio F, Dudek K, Langley S, Kiechl S , Warner T et al (2014) Plasma microRNA levels in patients with acute coronary syndrome are associated with platelet function. Atherosclerosis, Vol. 237(2) (pp e5-e5)
Iqbal J, Rowe R, Zhang Y-J, Parviz Y, Morton AC, Grech E, Gunn JP & Storey RF (2014) Lower Mortality and Stent Thrombosis Rates Associated With Introduction of Potent P2Y12 Inhibitors in Patients With Acute Coronary Syndromes. CIRCULATION, Vol. 130
Mayr M, Kaudewitz D, Skroblin P, Willeit P, Zampetaki A, Morton AC & Storey RF (2014) Plasma MicroRNAs Correlate With Platelet Reactivity in Patients With Acute Coronary Syndrome: Association With Platelet Function. CIRCULATION, Vol. 130
Ueland T, Aukrust P, Michelsen A, Bertilsson M, James SK, Himmelmann A, Siegbahn A, Storey R, Kontny F, Wallentin L & PLATO (2014) Secreted wingless (Wnt) antagonists and risk prediction in acute coronary syndrome (ACS) a PLATO biomarker substudy. EUROPEAN HEART JOURNAL, Vol. 35 (pp 318-318)
Oskarsson A, Varenhorst C, Hagstrom E, Wernroth ML, Becker RC, Held C, Himmelmann A, Storey RF, Wallentin L, James S & Investigators PLATO (2014) ApoA1 is independently associated with recurrent ischemic events and death in acute coronary syndrome patients. EUROPEAN HEART JOURNAL, Vol. 35 (pp 482-482)
Ueland T, Michelsen A, Aukrust P, Becker R, Bertilsson M, James SK, Siegbahn A, Storey RF, Wallentin L, Kontny F & PLATO (2014) Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy. EUROPEAN HEART JOURNAL, Vol. 35 (pp 486-486)
Thomas MR, Outteridge SN, Ecob R, Sangha GK, Faulkner RE, West LE, Judge HM, Dockrell DH, Sabroe I & Storey RF (2014) Ticagrelor inhibits release of pro-inflammatory cytokines TNF and IL-6 during human endotoxaemia. European Heart Journal, Vol. 35(Supp1) (pp 1170-1170), 30 August 2014 - 3 September 2014.
Alsharif K, Judge H, Ridger V & Storey RF (2014) Ticagrelor and dipyridamole potentiate adenosine-induced stimulation of neutrophil chemotaxis in the presence of erythrocytes. EUROPEAN HEART JOURNAL, Vol. 35 (pp 1031-1032)
Varenhorst C, Eriksson N, Johansson Å, Barratt B, Åkerblom A, Hagström E, Syvänen A-C, Becker R, James S, Katus H , Husted S et al (2014) TICAGRELOR PLASMA LEVELS BUT NOT CLINICAL OUTCOMES ARE ASSOCIATED WITH TRANSPORTER AND METABOLISM ENZYME GENETIC POLYMORPHISMS. Journal of the American College of Cardiology, Vol. 63(12) (pp A25-A25)
Velders M, Wallentin L, Becker R, van Boven AJ, Himmelmann A, Husted S, Lindholm D, Morais J, Siegbahn A, Storey R , Wernroth L et al (2014) ROLE OF ADMISSION CARDIAC BIOMARKERS IN RISK STRATIFICATION OF PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL. Journal of the American College of Cardiology, Vol. 63(12) (pp A18-A18)
Bui A, Cannon C, Steg P, Storey R, Husted S, Ren F, James S, Michelson E, Himmelmann A, Wallentin L & Scirica B (2014) RISK OF CARDIOVASCULAR DEATH AND NON-SUSTAINED VENTRICULAR TACHYCARDIA DETECTED 30-DAYS AFTER ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL. Journal of the American College of Cardiology, Vol. 63(12) (pp A298-A298)
Tricoci P, Chen E, Neely ML, Warner A, Wong PH, Sinnaeve P, Wallentin L, Jennings LK, Storey RF, Aylward PE , White HD et al (2013) CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS: Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial. CIRCULATION, Vol. 128(22)
Hagstrom E, Eriksson N, Johansson A, Bertilsson M, Axelsson T, Barratt BJ, Becker RC, Himmelmann A, James SK, Katus HA , Siegbahn A et al (2013) Are There Any Causal Relations Between Growth Differentiation Factor 15 and Outcomes in Patients With Acute Coronary Syndrome? - A Report From the Plato Gwas Study. CIRCULATION, Vol. 128(22)
Siegbahn A, Johansson A, Eriksson N, Hagstrom E, Varenhorst C, Akerblom A, Bertilsson M, Axelsson T, Barratt BJ, Becker RC , Himmelmann A et al (2013) Evaluation of the Effect of Interleukin 18 Associated Genetic Polymorphisms on Risk of Cardiovascular Events in Patients With Acute Coronary Syndrome. CIRCULATION, Vol. 128(22)
Morton AC, Hossain R, Ecob R, Walker J, Gunn J, Judge HM & Storey RF (2013) Morphine Delays the Onset of Action of Prasugrel in Patients With Prior History of St Elevation Myocardial Infarction. CIRCULATION, Vol. 128(22)
Kaudewitz D, Lee R, Willeit P, Zampetaki A, Morton AC, Warner TD, Storey RF, Channon K & Mayr M (2013) Impact of Medication on Quantification of Plasma MicroRNAs in Patients With Cardiovascular Disease. CIRCULATION, Vol. 128(22)
Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Himmelmann A, Husted S, Storey RF, Eriksson N, Johansson A & James SK (2013) Genetic Polymorphism and Relationship to Cystatin C Concentrations and Outcome - Results From the Platelet Inhibition and Patient Outcomes Study. CIRCULATION, Vol. 128(22)
Wallentin L, James S, Giannitsis E, Katus H, Becker RC, Cannon CP, Horrow J, Husted S, Siegbahn A, Steg GP , Storey RF et al (2013) Outcomes with ticagrelor versus clopidogrel in relation to high sensitivity troponin-T in non-ST-elevation acute coronary syndrome patients managed with early invasive or non-invasive treatment - a substudy from the prospective randomized PLATelet inhibit. PHARMACOTHERAPY, Vol. 33(10) (pp E189-E189)
Storey RF, Ardissino D, Vignali L, Cairns R, Becker RC, Cannon CP, Himmelmann A, Husted S, James SK & Wallentin L (2013) Ischaemic events following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. EUROPEAN HEART JOURNAL, Vol. 34 (pp 826-826)
Varenhorst C, Alstrom U, Braun OO, Storey RF, Mahaffey KW, Cannon C, Himmelmann A, James S, Wallentin L & Held C (2013) Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 34 (pp 827-827)
Hess KA, Kurdee Z, Oxley N, Phoenix F, Marx N, King R, Storey RF, Grant PJ & Ajjan RA (2013) Modulation of complement C3 levels and fibrin clot structure: the role of aspirin dose. EUROPEAN HEART JOURNAL, Vol. 34 (pp 891-891)
Wallentin LC, Bertilsson M, Becker RC, Himmelmann A, Husted S, James S, Katus H, Steg G, Storey RF, Siegbahn A & PLATO (2013) GDF-15 level in acute coronary syndrome and its relations to cardiovascular risk factors, disease manifestations, treatments and outcome - results from the PLATO-study. EUROPEAN HEART JOURNAL, Vol. 34 (pp 733-733)
James S, Storey RF, Cannon C, Janzon M, Nicolau JC, Parasuraman B, Mellstrom K, Wallentin L & Henriksson M (2013) Health economic evaluation of ticagrelor compared to generic clopidogrel in patients with acute coronary syndromes intended for non-invasive management based on the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 34 (pp 896-896)
Chow EYK, Iqbal A, Walkinshaw E, Solomon AL, Daly R, Judge HM, Storey RF & Heller SR (2013) Hypoglycemia Increases Platelet Reactivity in Patients With Type 2 Diabetes. DIABETES, Vol. 62 (pp A100-A100)
West L, Francis S & Storey R (2013) YIA6: VESSEL WALL, BUT NOT PLATELET, P2Y12 CONTRIBUTES TO EARLY ATHEROGENESIS. Heart, Vol. 99(suppl 2) (pp A7-A7)
Willeit P, Zampetaki A, Kaudewitz D, Lee R, Dudek K, King A, Kirkby NS, Markus HS, Warner TD, Kiechl S , Morton AC et al (2013) PLASMA MICRORNAS AS BIOMARKERS FOR PLATELET INHIBITION. HEART, Vol. 99
Bansilal S, Wiviott S, Becker R, Harrington R, Himmelmann A, Neely B, Husted S, Storey R, Steg P, Katus H , James S et al (2013) THE EFFICACY AND SAFETY OF TICAGRELOR AS COMPARED TO CLOPIDOGREL, WITH AND WITHOUT A GLYCOPROTEIN IIB/IIIA INHIBITOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS INTERVENTION: A PLATO (STUDY OF PLATELET INHIBITION AND PATIENT OUTCOMES) ANALYSIS. Journal of the American College of Cardiology, Vol. 61(10) (pp E1858-E1858)
Lindholm D, Varenhorst C, Cannon C, Harrington R, Himmelmann A, Maya J, Husted S, Katus H, Steg P, Storey R , Wallentin L et al (2013) TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: RESULTS FROM THE PLATO TRIAL. Journal of the American College of Cardiology, Vol. 61(10) (pp E1-E1)
Lee GA, Wyatt S, Topliss D, Walker KZ & Storey R (2013) A study of a preoperative intervention in patients with diabetes undergoing cardiac surgery. DIABETIC MEDICINE, Vol. 30 (pp 152-152)
Bright RJ, Storey RF & Chico TJ (2012) ZEBRAFISH AS A MODEL TO INVESTIGATE THE ROLES OF THE P2Y12 RECEPTOR IN VIVO. ATHEROSCLEROSIS, Vol. 225(2) (pp E1-E1)
Bueno H, Storey RF, Danchin N, Sanchez-Covisa J, Sazova O, Licour M, Annemans L, Jukema JW, Zeymer U & Van de Werf F (2012) Current regional differences in the use of antiplatelet drugs for the treatment of acute coronary syndromes. Results from the EPICOR study. EUROPEAN HEART JOURNAL, Vol. 33 (pp 311-311)
Tricoci P, Whellan DJ, Vranckx P, Leibovitz D, Huang Z, Strony J, Nicolau J, Storey RF, Chen E & Mahaffey K (2012) Vorapaxar in ACS patients undergoing CABG surgery: results from the TRACER trial. EUROPEAN HEART JOURNAL, Vol. 33 (pp 508-509)
Sinnaeve PR, Bueno H, Danchin N, Sanchez-Covisa J, Licour M, Annemans L, Jukema JW, Storey RF, Van de Werf F & Zeymer U (2012) Contemporary pre-hospital management of ACS patients: results from the EPICOR study. EUROPEAN HEART JOURNAL, Vol. 33 (pp 314-314)
Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Katus H, Claeys MJ, Storey RF, Asenblad N, James SK & Outcom PIP (2012) Serial cystatin C measurements and changes in glomerular filtration rate as predictors for death or myocardial infarction in ACS patients. EUROPEAN HEART JOURNAL, Vol. 33 (pp 135-135)
Sinnaeve PR, Bueno H, Danchin N, Sanchez-Covisa J, Licour M, Annemans L, Jukema JW, Storey RF, Zeymer U & Van De Werf F (2012) Availability of cath lab facilities and contemporary inter-hospital transfer patterns for the management of ACS patients: findings from the EPICOR study. EUROPEAN HEART JOURNAL, Vol. 33 (pp 145-145)
Wallentin L, James S, Storey R, Barratt B, Horrow J, Husted S, Katus H, Steg P & Becker R (2012) GREATER EFFICACY OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME IS NOT DRIVEN BY OUTCOMES IN POOR METABOLIZERS OF CLOPIDOGREL. Journal of the American College of Cardiology, Vol. 59(13) (pp E500-E500)
Jennings LK, Moliterno D, Storey R, Hord E, Kotha J, Becker R, Smyth S, Providencia L, Moccetti T, Valgimigli M , Dery J-P et al (2012) PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL. Journal of the American College of Cardiology, Vol. 59(13) (pp E351-E351)
Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Storey R, James S & Cannon C (2012) REDUCTION IN FIRST AND RECURRENT CARDIOVASCULAR AND ISCHEMIC EVENTS WITH TICAGRELOR COMPARED WITH CLOPIDOGREL IN THE PLATO STUDY. Journal of the American College of Cardiology, Vol. 59(13) (pp E504-E504)
Wallentin L, James S, Giannitsis E, Katus H, Becker R, Cannon C, cornel J, Emanuelsson HAK, Husted S, Harrington R , Steg P et al (2012) USEFULNESS OF BIOMARKERS FOR PROGNOSTICATION OF OUTCOME WITH EARLY INVASIVE OR NONINVASIVE TREATMENT IN NON-ST-ELEVATION ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 59(13) (pp E497-E497)
Cornel JH, Becker R, Goodman S, Husted S, Katus H, Santoso A, Steg P, Storey R, Vintila M, sun J , Horrow J et al (2012) PRIOR SMOKING STATUS, CLINICAL OUTCOMES, AND THE COMPARISON OF TICAGRELOR WITH CLOPIDOGREL IN ACUTE CORONARY SYNDROMES – INSIGHTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 59(13) (pp E495-E495)
Bui AH, Cannon C, Steg P, Storey R, Husted S, Ren F, James S, Michelson E, Horrow J, Wallentin L & Scirica B (2012) RELATIONSHIP BETWEEN NONSUSTAINED VENTRICULAR TACHYCARDIA AND VASCULAR DEATH IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL. Journal of the American College of Cardiology, Vol. 59(13) (pp E629-E629)
Husted S, James S, Becker R, Horrow J, Katus H, Storey R, Cannon C, Heras M, Lopes R, Morais J , Mahaffey K et al (2012) TICAGRELOR VERSUS CLOPIDOGREL IN WOMEN WITH ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 59(13) (pp E507-E507)
Storey RF, Steg P, James S, Husted S, Cannon C, Becker R, Ycas J, Asenblad N, Kilhamn J & Wallentin L (2012) REDUCTION IN PULMONARY ADVERSE EVENTS AND ASSOCIATED SEPSIS AND MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS TREATED WITH TICAGRELOR COMPARED TO CLOPIDOGREL: A POST HOC ANALYSIS OF THE PLATO STUDY. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 59(13) (pp E482-E482)
Storey RF, James S, Asenblad N, Siegbahn A, Emanuelsson H, Katus H, Cannon C, Husted S, Steg P & Wallentin L (2012) CONSISTENT BENEFIT OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS REGARDLESS OF BASELINE INFLAMMATORY MARKERS. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 59(13) (pp E505-E505)
Karunakaran A, Judge H, Morton A, Milano A, Arnold J, Chico TJ, Flaherty L, Baker D, Daly R & Storey RF (2011) Cytochrome P450 2C19 Loss-Of-Function Genetic Variants but not Paraoxonase-1 Activity Modulate P2Y12 Blockade in Response to Clopidogrel Therapy. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 58(20) (pp B45-B45)
Kunadian V, Zorkun C, James S, Wu J, Muhammad A, Storey R, Steg PG, Katus H, Emanuelsson H, Horrow J , Maya J et al (2011) ANGIOGRAPHIC OUTCOMES IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 57(14) (pp E946-E946)
Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J , Mahaffey KW et al (2011) TICAGRELOR VERSUS CLOPIDOGREL IN ELDERLY PATIENTS WITH ACUTE CORONARY SYNDROMES: A SUBANALYSIS FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 57(14) (pp E1099-E1099)
Åkerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, Horrow J, Husted S, Katus H, Steg PG , Storey RF et al (2011) CYSTATIN C IS AN INDEPENDENT RISK PREDICTOR FOR DEATH OR MYOCARDIAL INFARCTION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) AS WELL AS IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME (NSTE-ACS). Journal of the American College of Cardiology, Vol. 57(14) (pp E999-E999)
Goodman SG, Clare R, Pieper KS, James SK, Nicolau JC, Storey RF, Cantor WJ, Angiolillo DJ, Husted S, Cannon CP , Steg PG et al (2010) Proton Pump Inhibitor Use is Likely a Marker for, Rather than a Cause of, a Higher Risk of Cardiovascular Events: Insights from PLATO. CIRCULATION, Vol. 122(21)
Pandya A, Ermolina I, Storey R & Smith G (2010) Relationship between ATP hydrolysis and molecular dynamics in co-freeze-dried sugar-ATP mixtures. JOURNAL OF PHARMACY AND PHARMACOLOGY, Vol. 62(10) (pp 1465-1467)
Storey RF, Bliden KP, Patil SB, Karunakaran A, Ecob R, Butler K, Wei C, Tantry U & Gurbel PA (2010) Earlier recovery of platelet function after treatment cessation in ticagrelor-treated patients compared to clopidogrel high responders. EUROPEAN HEART JOURNAL, Vol. 31 (pp 389-389)
Patil SB, Angiolillo DJ, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L & Storey RF (2010) Platelet inhibition by ticagrelor is not affected by proton pump inhibitors: results from the PLATO PLATELET substudy. EUROPEAN HEART JOURNAL, Vol. 31 (pp 905-906)
James S, Angiolillo DJ, Becker RC, Cornel JH, Horrow J, Husted S, Katus H, Nicolau JC, Storey RF & Wallentin L (2010) Ticagrelor versus clopidogrel in patients with acute coronary syndromes and diabetes in the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 31 (pp 202-202)
Storey RF, Becker RC, Harrington RA, Cannon CP, Husted S, James SK, Cools F, Steg PG, Khurmi N & Wallentin L (2010) Increased incidence of dyspnoea associated with ticagrelor did not appear to adversely affect cardiovascular outcomes in the PLATO study. EUROPEAN HEART JOURNAL, Vol. 31 (pp 203-203)
James S, Roe MT, Cannon CP, Raev D, Horrow J, Husted S, Kontny F, Storey RF, Wallentin L & Harrington R (2010) Ticagrelor versus clopidogrel in patients with Acute Coronary Syndromes intended for a non-invasive management in the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 31 (pp 203-203)
Storey RF, Bliden K, Patil SB, Karunakaran A, Ecob R, Butler K, Teng RL & Gurbel P (2009) The Effect of Ticagrelor on Cardiopulmonary Function in Patients With Stable Coronary Artery Disease. CIRCULATION, Vol. 120(18) (pp S1145-S1145)
Gurbel P, Bliden K, Antonino M, Butler K, Teng RL, Rasmussen L, Storey RF, Nielsen T, Eikelboom J, Sabe-Affaki G , Husted S et al (2009) The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study. CIRCULATION, Vol. 120(18) (pp S1173-S1173)
Husted SE, Gurbel P, Storey RF, Bliden K, Hoimark L, Antonino MJ, Mahla E, Tantry U, Butler K, Wei C & Teng RL (2009) Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Coronary Artery Disease. CIRCULATION, Vol. 120(18) (pp S1102-S1102)
Storey RF, Patil SB, Ecob R, Angiolillo DJ & Wallentin L (2009) More Rapid and Consistent Inhibition of Platelet Aggregation is Achieved by Loading With Ticagrelor Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy. CIRCULATION, Vol. 120(18) (pp S1102-S1102)
Gurbel P, Bliden K, Butler K, Tantry U, Teng RL, Antonino M, Patil SB, Karunakaran A, Kereiakes D, Paris C , Purdy D et al (2009) A Randomized Double-Blind Study to Assess the Onset and Offset of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients With Stable Coronary Artery Disease. CIRCULATION, Vol. 120(18) (pp S1143-S1143)
Storey RF, Angiolillo DJ, Patil SB, Desai B, Husted S, Emanuelsson H & Wallentin L (2009) Maintenance Treatment With Ticagrelor Yields Greater and More Consistent Inhibition of Platelet Function Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy. CIRCULATION, Vol. 120(18) (pp S1027-S1027)
Cannon CP, Becker R, Emanuelsson H, Harrington R, Horrow J, Husted S, Katus H, Steg PG, Storey RF & Wallentin L (2009) PLATO-Invasive: Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes with a planned invasive strategy: Results of the PLATelet inhibition and patient Outcomes (PLATO) trial. AMERICAN JOURNAL OF CARDIOLOGY, Vol. 104(6A) (pp XVIII-XVIII)
Patil SBG, Judge HM, Buckland RJ & Storey RF (2009) RIFAMPICIN INCREASES THE EXTENT OF P2Y12 RECEPTOR BLOCKADE ACHIEVED BY CLOPIDOGREL ADMINISTRATION. HEART, Vol. 95 (pp A51-A52)
Pandya A, Ermolina I, Storey R & Smith G (2009) High-performance liquid chromatography method development for studying the degradation of freeze-dried adenosine triphosphate when stored at 4 and 40 degrees C. JOURNAL OF PHARMACY AND PHARMACOLOGY, Vol. 61 (pp A130-A130)
Patil SBG, Judge HM, Buckland RJ, Jakubowski JA & Storey RF (2009) Rifampicin increases the extent of P2Y12 receptor blockade achieved by clopidogrel administration. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 7 (pp 105-105)
Buckland RJ, Judge HM, Sugidachi A, Jakubowski JA & Storey RF (2009) Reversible binding of cangrelor to the P2Y12 receptor prevents the binding of clopidogrel and prasugrel active metabolites. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 7 (pp 942-942)
Storey RF (2008) New developments in antiplatelet therapy. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 10(D) (pp D30-D37)
Evans DJW, Crosdale DJ, Judge HM, Chamberlain J, Jetha K, Norman KE, Francis SE & Storey RF (2008) The platelet P2Y12 receptor influences the vessel wall response to arterial injury and thrombosis. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 51(10) (pp A291-A291)
Storey RF (2008) Variability of response to antiplatelet therapy. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 10(A) (pp A21-A27)
Smith SMG, Buckland R, Daly ME & Storey RF (2007) Inhibition of platelet aggregation by clopiclogrel is unaffected by the CYP2C19 681G > A polyrnorphism in patients with coronary artery disease. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 49(9) (pp 375A-375A)
Storey RF, Cannon CP, Harrington RA, Sandset PM, Helptinstall S, Wickens M, Peters G, Emanuelsson H, Price D & Husted S (2006) AZD6140 exerts greater inhibition of platelet aggregation than clopidogrel in patients with stable atherosclerotic disease or unstable coronary disease. CIRCULATION, Vol. 114(18) (pp 698-699)
Husted S, Harrington RA, Cannon CP, Storey RF, Wickens M, Price D & Emanuelsson H (2006) AZD6140, a reversible oral ADP receptor antagonist, does not increase risk of bleeding vs the thienopyridine clopidogrel in patients undergoing CABG surgery in the DISPERSE2 trial. AMERICAN JOURNAL OF CARDIOLOGY, Vol. 98(8A) (pp 204M-204M)
Smith SMG, Judge HM, Daly ME & Storey RF (2006) The G allele of the platelet P2Y1 1622 A > G polymorphism is not associated with platelet hyper-reactivity to ADP in either healthy volunteers or CAD patients. EUROPEAN HEART JOURNAL, Vol. 27 (pp 756-756)
Evans D, Crosdale DJ, Norman KE, Francis SE & Storey RF (2006) The P2Y12 receptor regulates the vessel wall response to arterial injury and thrombosis. EUROPEAN HEART JOURNAL, Vol. 27 (pp 753-753)
Evans D, Crosdale D, Norman K, Francis S & Storey R (2006) The P2Y12 receptor regulates the vessel wall response to arterial injury and thrombosis. HEART, Vol. 92 (pp A111-A111)
Smith S, Judge H, Daly M & Storey R (2006) Platelet protease-activated receptor 1 density, trap-induced platelet responses, and the effect of complete P2Y(12) receptor blockade. HEART, Vol. 92 (pp A111-A112)
Husted S, Storey RF, Harrington RA, Sanders N, Peters G, Emanuelsson H & Cannon CP (2006) The effects of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel on biochemical markers in patients with acute coronary syndromes (ACS). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 200A-200A)
Cannon CP, Harrington RA, Mahaffey KW, Husted S, Storey RF, Sanders N, Peters G & Emanuelsson H (2006) Clinical outcomes with AZD6140, an oral reversible ADP receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes (ACS). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 199A-200A)
Emanuelsson H, Mahaffey KW, Harrington RA, Husted S, Storey RF, Sanders N, Peters G & Cannon CP (2006) Greater inhibition of platelet aggregation be tolerated? - Evaluation of the bleeding risk of AZD6140 compared with clopidogrel (CLOP) in patients with acute coronary syndromes (ACS). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 212A-212A)
Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Gurbel PA, Grande P, Sanders N, Peters G, Emanuelsson H & Cannon CP (2006) AZD6140 yields greater inhibition of platelet aggregation than clopidogrel in patients with acute coronary syndromes without previous clopidogrel treatment. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 204A-204A)
Storey RF, Harrington RA, Husted S, Heptinstall S, Wilcox RG, Gurbel PA, Grande P, Sanders N, Peters G, Emanuelsson H & Cannon CP (2006) AZD6140 yields additional suppression of platelet aggregation in patients with acute coronary syndromes previously treated with clopidogrel. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 204A-204A)
Cannon CP, Husted S, Storey RF, Harrington RA, Hill S, Price D, Sanders N, Emanuelsson H, Peters G & DISPERSE 2 Investigators (2005) The DISPERSE2 trial: Safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non-ST segment elevation acute coronary syndrome. CIRCULATION, Vol. 112(17) (pp U677-U677)
Smith SMG, Judge HM, Peters G, Armstrong M, Fontana P, Gaussem P & Storey RF (2005) Common sequence variations in the P2Y12 and CYP3A5 genes do not explain variability in the inhibitory effects of clopidogrel therapy. EUROPEAN HEART JOURNAL, Vol. 26 (pp 486-486)
Judge H, Buckland R, Crosdale D & Storey RF (2005) Partial P2Y12 receptor blockade by clopidogrel may not be overcome by increasing the clopidogrel dose. EUROPEAN HEART JOURNAL, Vol. 26 (pp 487-487)
Shrivastava V, Akowuah E, Jamnadas B, Storey R, Matuszewski M, Pradeep S, Hopkinson DN, Braidley PC & Cooper GJ (2004) A randomized double blind comparison of two strategies for managing patients on aspirin and clopidogrel therapy requiring urgent coronary revascularization. CIRCULATION, Vol. 110(17) (pp 356-356)
Smith SMG, Judge HM, Peters G, Armstrong M, Fontana P, Gaussem P & Storey RF (2004) Gene sequence variations influence platelet reactivity before and during clopidogrel therapy. EUROPEAN HEART JOURNAL, Vol. 25 (pp 237-237)
Smith SMG, Judge HM, Peters G & Storey RF (2004) Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. HEART, Vol. 90 (pp A31-A31)
Behan MWH, Fox SC, Storey RF & Heptinstall S (2003) Effects of clopidogrel on platelet calcium mobilisation in acute coronary syndrome patients. EUROPEAN HEART JOURNAL, Vol. 24 (pp 323-323)
Behan MW, Fox S, Sanderson H & Storey R (2002) Effect of clopidogrel on procoagulant activity in acute coronary syndromes: Evidence for incomplete P2Y12 receptor blockade. CIRCULATION, Vol. 106(19) (pp 149-150)
Storey RF, Judge HM, Wilcox RG & Heptinstall S (2002) Inhibition of ADP-induced platelet-leukocyte conjugate formation by clopidogrel and AR-C69931MX. EUROPEAN HEART JOURNAL, Vol. 23 (pp 722-722)
Storey RF (2001) Clinical experience with antithrombotic drugs acting on purine receptor pathways. DRUG DEVELOPMENT RESEARCH, Vol. 52(1-2) (pp 202-212)

Other

James SK, Storey RF, Pieper KS, Cannon CP, Becker RC, Steg PG, Wallentin L & Harrington RA (2013) Response to letter regarding article, "ticagrelor in patients with acute coronary syndromes and stroke: Interpretation of subgroups in clinical trials". Stroke, 44(8).

Preprints

Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O’Brien R, Storey RF, Curzen N, Keating L, Kardos A , Felmeden D et al () Randomised Controlled Trial of Early CT Coronary Angiography in Patients With Suspected Acute Coronary Syndrome.

Research group

PhD Students

Dr William Parker
Dr Wael Sumaya

MD Students

Dr Rachel Orme
Dr Vatchsala Sree Varadharajan

Teaching activities: I am currently coordinator for the first year medical undergraduate Cardiovascular System module.

Professional activities and memberships

2019: Research of the Year award, British Cardiovascular Intervention Society.
2017: Member of the BHF Fellowships Committee.
2015-2019: Member of the NIHR EME board.
2000: DM with distinction, 'Novel platelet antagonists in the management of ischaemic heart disease', University of Nottingham.
1999: Young Investigators Award, International Society of Thrombosis and Haemostasis.

School of Medicine and Population Health

School of Medicine and Population Health

Professor Robert Storey

Current projects

Featured publications

Journal articles

All publications

Journal articles

Chapters

Conference proceedings papers

Other

Preprints

PhD Students

MD Students

Links